

CURRICULUM VITAE

GARY REMINGTON, MD, PhD, FRCP(C)

**Complex Mental Illness Program
Schizophrenia Division
Centre for Addiction and Mental Health
250 College Street
Toronto, Ontario M5T 1R8
Telephone: (416) 535-8501 Ext. 4750
Fax: (416) 979-4292
E-mail: gary.remington@camh.ca**



**Department of Psychiatry
Faculty of Medicine
School of Graduate Studies, Institute of Medical Science
University of Toronto**



**Psychiatry
UNIVERSITY OF TORONTO**

A. Date of CV Preparation

August 12, 2015

B. Biographical Information**B.1. Degrees**

Degree	Institution	Year	Specialty
PhD	Carleton University	1977	Experimental Psychology (Psychopharmacology)
MD	McMaster University	1980	Medicine
FRCPC	University of Toronto	1984	Psychiatry

Ph.D. THESIS:

Genetic and ontogenetic variations in catecholaminergic and cholinergic development: a model for hyperkinesis.

B.2. Employment

Position	Years
Schizophrenia Lead, Division of Brain and Therapeutics University of Toronto	2010-present
Professor Department of Psychiatry, Faculty of Medicine University of Toronto	2002-present
Full-Time Faculty Institute of Medical Science School of Graduate Studies University of Toronto	2002-present
Deputy Head, Research & Education Schizophrenia Program Centre for Addiction and Mental Health	1999-2013
Clinician Scientist Schizophrenia Program, CAMH	1993-present
Campbell Research Institute, CAMH (cross-appointed)	2012-present

Director, Medication Assessment Program for Schizophrenia (MAPS) Clinic Schizophrenia Program Centre for Addiction and Mental Health	1998-2013
Graduate Faculty Institute of Medical Science University of Toronto	2002-present
Graduate Faculty Department of Psychological Clinical Science University of Toronto Scarborough	2014-present
<i>B.3. Professional Affiliations, Activities, Awards</i>	
Laughlin Fellow, American College of Psychiatrists	1984
World Health Organization Task Force on Neuroleptics	1990
Psychopharmacology Consultant Canadian Medical Protective Association	1993-1994
Examiner Royal College of Physicians and Surgeons of Canada	1991-1996
Psychopharmacology Panel Canadian Alliance for Research on Schizophrenia (CAROS)	1990-1996
Psychopharmacology Consultant College of Physicians and Surgeons of Ontario	1990-1991
International Classification of Mental and Behavioural Disorders, 10 th Edition (ICD-10) Field Trials, Principal Investigator	1992
Founding Member & International Advisory Board International Early Psychosis Association (IEPA)	1997-present
World Psychiatric Association Consensus Statement on the Use of Antipsychotic Drugs	1999
Board of Advisors, Woodbridge Hospital Singapore	2000-present
Canadian Institutes of Health Research (CIHR) University-Industry Committee	2002-2005

Canadian College of Neuropsychopharmacology (CCNP) Public Relations & Liaison Committee	2002-2006
Hofmann Trust Investigator (NARSAD Research Partners Program)	2002-2003
Expert Consensus Guidelines: Optimizing Pharmacologic Treatment of Psychotic Disorders (J Clin Psychiatry 2003; 64[Suppl 12])	2003
American Psychiatric Association on Antipsychotics and Metabolic Risk	2005
DSM-V Workgroup on Apathy	2005-present
International Antipsychotic Clinically Equivalent Dose (ACE- Dose) Survey	2008-2009
Canadian Institutes of Health Research (CIHR) Behavioural Sciences B	2008-2009
Expert Consensus Guidelines: Antipsychotic Dosing (Am J Psychiatry 2010; 167:686-693)	2010
International Congress on Schizophrenia Research Program Committee	2009-2011
Canadian Optimal Medication and Prescribing Utilization Service (COMPUS) Expert Review Committee (CERC), Canadian Agency for Drugs and Technologies in Health (CADTH)	2010-2011
Paul Garfinkel Award, Best Fellowship Supervisor, University of Toronto, Department of Psychiatry	2010-2011
Pfizer Psychiatry Research Awards Committee	2011-
Scientific Advisory Council, Schizophrenia Society of Ontario (SSO)	2011-
Organizing Committee, NIH-Sponsored Conference: Adipogenic and Metabolic Side Effects of Antipsychotic Drugs	July, 2011
Best Poster Award (Agid O, Siu C, Potkin S, McDonald K, Remington G) European College of Neuropsychopharmacology, Paris, France, Sept 37, 2011	September 2011
Mel Silverman Mentorship Award 2012, Institute of Medical Science, University of Toronto	May 2012
Innovations in Neuropsychopharmacology Award, Canadian College of Neuropsychopharmacology	May 2012

Paul Garfinkel Award, Best Fellowship Supervisor, University of Toronto, Department of Psychiatry 2012-13

Japanese Society of Clinical Neuropsychopharmacology Meeting, November 2014
 Paul Janssen Award (Takeuchi H, Suzuki T, Remington G et al. Effects of risperidone and olanzapine on cognitive function in stable patients with schizophrenia. Schizophr Bull 2013; 39:993-998)

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

Canadian Cochrane Network (CCN)
 Canadian College of Neuropsychopharmacology (CCNP)
 Canadian Medical Association (CMA)
 Canadian Psychiatric Association (CPA)
 College of Physicians and Surgeons of Ontario (CPSO)
 International Early Psychosis Association (IEPA)
 International Network for the History of Neuropsychopharmacology (INHN)
 Ontario Psychiatric Association (OPA)
 Royal College of Physicians and Surgeons of Canada (RCPSC)
 Schizophrenia International Research Society (SIRS) [incl. Education, Publication Committees]

AD HOC EXTERNAL REVIEWER:

(a) FOUNDATIONS AND GROUPS

Alberta Health Services Research and Innovation Fund
 Canadian Diabetes Association
 Canadian Psychiatric Research Foundation
 Eli Lilly Research Foundation
 Fonds de la Recherche en Sante du Quebec (FRSQ)
 Israel Science Foundation
 Ontario Mental Health Foundation
 Medical Research Council of Canada
 Medical Research Council (England)
 National Institute of Mental Health (USA)
 National Medical Research Council (Singapore)
 Ontario Ministry of Health
 Wellcome Trust (England)
 Dean's Fund, Department of Medicine, University of Toronto

(b) JOURNALS

American Journal of Psychiatry
 Archives of General Psychiatry
 Biological Psychiatry
 BMC Neurology
 BMC Psychiatry
 Bulletin of the World Health Organization

Canadian Journal of Clinical Pharmacology
 Canadian Journal of Psychiatry
 Canadian Medical Association Journal
 Clinical Neuropharmacology
 Clinical Pharmacology and Therapeutics
 CNS Drugs
 Drugs
 European Psychiatry
 Evidence Based Mental Health (British Medical Journal)
 Expert Opinion on Investigational Drugs
 Expert Opinion on Pharmacotherapy
 Expert Opinion on Therapeutic Targets
 Expert Review of Neurotherapeutics
 International Clinical Psychopharmacology
 International Journal of Neuropsychopharmacology
 Investigational Drugs
 JAMA
 JAMA Psychiatry
 Journal of Clinical Pharmacology
 Journal of Clinical Psychiatry
 Journal of Clinical Psychopharmacology
 Journal of Nervous and Mental Disease
 Journal of Psychiatry & Neuroscience
 Lancet Psychiatry
 Lancet
 Nature Reviews
 Neuropsychopharmacology
 Neuroscience
 New England Journal of Medicine
 Pharmacy and Therapeutics
 Progress in Neuro-psychopharmacology and Biological Psychiatry
 Psychiatry Research
 Psychological Medicine
 Schizophrenia Bulletin
 Schizophrenia Research

EDITORIAL BOARDS:

Title	Date
Journal of Clinical Psychiatry (Case and Comment Series)	1995 - 1996
Compendium of Pharmaceuticals and Specialties (CPS)	1998 - 2009
Clinical Schizophrenia & Related Psychoses	2006 -
Advances in Therapy	2008 -
Drugs in R&D	2010 -
Current Psychopharmacology	2011 -

C. Academic History

C.1. Research

Schizophrenia and its pharmacology

Antipsychotics – Clinical

Use in the clinical setting for schizophrenia

- a. Clinical trials evaluating antipsychotics
- b. Guidelines for dosing and choice of antipsychotic
- c. Refractory schizophrenia and augmentation strategies
- d. The evaluation of side effects e.g., weight gain, EPS
- e. The investigation of compliance and contributing factors

Antipsychotics – Biochemical

The evaluation of antipsychotics and their mechanisms of action

- a. Use of PET to evaluate comparative receptor binding in the novel antipsychotics i.e., 5-HT₂/D₂ profile
- b. The evaluation of D₂ occupancy and its relationship to clinical response and D₂-related side effects
- c. The evaluation of D₂ transience and its clinical implications
- d. Animal models for evaluating antipsychotic potential and risk of side effects
- e. Conceptual frameworks for categorizing antipsychotics based on mechanisms of action

C.2. Research Awards (Title/Amount/Source/Duration)

Principal and Co-Principal Investigator

Name of Agency:	Merrell Dow Pharmaceuticals
Date of Award:	1987-1990
Project Title:	A comparison of zuclopenthxol acetate and intramuscular haloperidol in the treatment of acutely psychotic patients
Total Amount:	\$154,000
PI	G. Remington
Co-Investigators	H. Rosenblat, G. Voineskos
Name of Agency:	Janssen Research Foundation
Date of Award:	1989-1990
Project Title:	A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
Total Amount:	\$96,000
PI:	G. Remington
Co-PIs:	G. Chouinard, B. Jones, D. Bloom, D. Addington, G. W. MacEwan, A. Labelle, L. Beauclair

Name of Agency: Clarke Institute Research Fund
Date of Award: 1989-1990
Project Title: **The quantitative assessment of akathisia**
Total Amount: \$1,750
PI: G. Remington

Name of Agency: Ontario Mental Health Foundation (OMHF)
Date of Award: 1989-1990
Project Title: **The quantitative assessment of akathisia**
Total Award: \$14,375
PI: G. Remington

Name of Agency: Canadian Psychiatric Research Foundation (CPRF)
Date of Award: 1989-1990
Project Title: **Neuroleptic-induced movement disorders: akathisia**
Total Amount: \$34,000
PI: G. Remington

Name of Agency: Sandoz Pharmaceuticals
Date of Award: 1990-1991
Project Title: **A prospective randomized placebo-controlled multi-center parallel-group comparison of the efficacy and safety of amperozide in low (1-5 mg), high (7.5-12.5 mg) dose, and haloperidol (10-30 mg) in institutionalized schizophrenics**
Total Award: \$200,000
Centre PI: G. Remington

Name of Agency: Janssen Research Foundation
Date of Award: 1991-1992
Project Title: **Risperidone (R 64766) in the treatment of first admission psychotic patients: an international, multicenter, double-blind, parallel-group study**
Total Award: \$35,000
Centre PI: G. Remington

Name of Agency: Sandoz Pharmaceuticals
Date of Award: 1992
Project Title: **Synaptic transmission blockade in the hippocampus with clozapine, an atypical neuroleptic**
Total Award: \$7,500
Co-PIs: A. Baskys, G. Remington

Name of Agency: Clarke Institute Research Fund
Date of Award: 1992-1993
Project Title: **Insight, negative symptomatology, and neurocognitive functioning in chronic schizophrenia**
Total Award: \$3,000
PI: G. Remington

Co-PI: A. Collins
 Co-Investigators: K. Coulter, K. Birkett

Name of Agency: Janssen Research Foundation
 Date of Award: 1992-1993
 Project Title: **Risperidone (R 64766) once daily versus twice daily in the treatment of acute exacerbations of schizophrenia: an international, multicenter, double-blind parallel trial group trial**

Total Award: \$132,000
 Centre PI: G. Remington

Name of Agency: Janssen Research Foundation
 Date of Award: 1992-1993
 Project Title: **Clinical evaluation of the efficacy and tolerability of ritanserlin as add-on therapy to depot neuroleptics in patients with predominantly negative symptoms of chronic and sub-chronic schizophrenia**

Total Award: \$146,160
 Centre PI: G. Remington

Name of Agency: Sandoz Pharmaceuticals
 Date of Award: 1992-1993
 Project Title: **A double-blind, placebo-controlled, parallel-group rising oral dose study of the safety, tolerability and efficacy of SDZ MAR 327 in hospitalized patients with schizophrenic disorders**

Total award: \$108,000
 Centre PI: G. Remington

Name of Agency: Janssen Research Foundation
 Date of Award: 1993-1994
 Project Title: **Risperidone (R 64766) versus haloperidol in treatment resistant chronic schizophrenic patients: a multicenter double-blind trial**

Total Award: \$110,000
 Centre PI: G. Remington

Name of Agency: Janssen Research Foundation
 Date of Award: 1993-1994
 Project Title: **Long-term safety of risperidone in the treatment of psychotic patients: an international multicenter open label trial**

Total Award: \$35,000
 Centre PI: G. Remington

Name of Agency: Zeneca Pharmaceuticals
 Date of Award: 1993-1994
 Project Title: **A multicenter, double-blind, randomized, controlled, multiple fixed dose and dose regimen comparison of seroquel (ICI 204,636) and haloperidol in the prevention of psychotic relapse in outpatients with chronic and subchronic schizophrenia**

Total Award: \$193,873
Centre PI: G. Remington

Name of Agency: Ontario Mental Health Foundation (OMHF)
Date of Award: 1993-1996
Project Title: **Differential effects of clomipramine versus haloperidol in the treatment of autistic disorder**

Total Award: \$86,730
PI: G. Remington
Co-PIs: L. Sloman, M. Konstantareas

Name of Agency: Abbott Laboratories
Date of Award: 1994-1995
Project Title: **A double-blind, placebo-controlled dose response comparison of the safety and efficacy of three doses of sertindole and three doses of haloperidol in schizophrenic patients**

Total Award: \$142,000
Centre PI: G. Remington

Name of Agency: Abbott Laboratories
Date of Award: 1994-1995
Project Title: **An open label assessment of the long-term safety of sertindole in the treatment of schizophrenic patients**

Total Award: \$95,000
Centre PI: G. Remington

Name of Agency: Sandoz
Date of Award: 1994-1995
Project Title: **A double-blind, parallel group, multicenter comparison of the efficacy and tolerability profile of clozapine versus risperidone in the management of treatment resistant schizophrenia**

Total Award: \$125,500
PI: G. Remington
Co-PI: J.-M. Azorin

Name of Agency: Eli Lilly Canada, Inc.
Date of Award: 1994-1996
Project Title: **Olanzapine versus haloperidol and risperidone in the treatment of schizophrenia and related psychotic disorders**

Total Award: \$125,500
Centre PI: G. Remington

Name of Agency: Janssen Research Foundation
Date of Award: 1995-1997
Project Title: **D₂ dopamine and 5-HT₂ serotonin receptor occupancy in patients on stable doses of risperidone**

Total Amount: \$126,4000
PI: G. Remington

Co-PI: S. Kapur
 Co-Investigators: R. B. Zipursky, M. Seeman

Name of Agency: Watson Laboratories
 Date of Award: 1998
 Project Title: **Plasma loxapine levels, metabolites and clinical response**
 Total Award: \$15,000
 PI: G. Remington

Name of Agency: Eli Lilly Canada, Inc.
 Date of Award: 1998
 Project Title: **Zyprexa (olanzapine) in schizophrenia and related psychotic disorders: an open-label naturalistic study**
 Total Award: \$28,000
 PI: G. Remington
 Co-PIs: R. Dickson, E. Stip

Name of Agency: Janssen Pharmaceutica Inc.
 Date of Award: 1998-1999
 Project Title: **A psychoeducation program for schizophrenia**
 Total Award: \$196,803
 PI: G. Remington
 Co-PI: A. Collins

Name of Agency: Ian Douglas Bebensee Foundation
 Date of Award: 1999-2000
 Project Title: **Switching antipsychotics: abrupt discontinuation versus overlap**
 Total Award: \$38,975
 PI: G. Remington
 Co-Investigator: C. Shammi

Name of Agency: Janssen Pharmaceutica Inc.
 Date of Award: 1998-1999
 Project Title: **Determination of D₂ and 5-HT₂ occupancy for risperidone depot: a PET study**
 Total Award: \$117,360
 PI: G. Remington
 Co-PI: S. Kapur

Name of Agency: National Medical Research Council (Singapore) MH 95:03/1-14
 Date of Award: 1998-1999
 Project Title: **Clinical characteristics and associated factors in neuroleptic-induced akathisia**
 Total Award: \$31,100
 PI: G. Remington
 Co-PI: S.A. Chong, R. Mahendran

Name of Agency: Janssen Pharmaceutica Inc.

Date of Award: 1998-1999
 Project Title: **Risperidone depot (microspheres) in the treatment of subjects with schizophrenia or schizoaffective disorder – an open label follow-up trial**
 Total Award: \$24,200
 Centre PI: G. Remington

Name of Agency: Pfizer Canada Inc.
 Date of Award: 1999-2000
 Project Title: **The 5-HT₂ and D₂ receptor occupancy of ziprasidone in patients with schizophrenia and schizoaffective disorder using PET**
 Total Award: \$248,400
 PI: G. Remington
 Co-PI: S. Kapur

Name of Agency: Pfizer Canada Inc.
 Date of Award: 1999-2000
 Project Title: **Open extension study evaluating the safety and tolerability of oral ziprasidone in the treatment of patients with schizophrenia and schizoaffective disorder**
 Total Award: \$48,000
 Centre PI: G. Remington

Name of Agency: Janssen-Ortho Pharmaceutica Inc.
 Date of Award: 2000-2001
 Project Title: **Cardiovascular health risks associated with antipsychotic use**
 Total Award: \$170,843
 PI: G. Remington
 Co-PI: T. Cohn

Name of Agency: Janssen-Ortho Pharmaceutica Inc.
 Date of Award: 2001-2002
 Project Title: **Topiramate augmentation in clozapine-refractory schizophrenia**
 Total Award: \$148,400
 PI: G. Remington
 Co-PI: T. Cohn

Name of Agency: NARSAD
 Date of Award: 2002-2004
 Project Title: **Extended doing with antipsychotics: rationale and evaluation**
 Total Award: \$98,289 (US)
 PI: Gary Remington
 Co-PI: (None) Independent Investigator Award

Name of Agency: Stanley Medical Research Institute
 Date of Award: 2002-2004
 Project Title: **Augmentation of clozapine partial responders with tetrabenazine**
 Total Award: \$176,637 (US)

PI: Gary Remington
 Co-PI: Shitij Kapur

Name of Agency: Canadian Diabetes Association
 Date of Award: 2008-2011
 Project Title: **The direct effect of antipsychotics on glucose dysregulation**
 Total Award: \$248,000
 PI: Gary Remington
 Co-I: T. Cohn, T. Wolever, P. Fletcher

Name of Agency: Canadian Foundation for Innovation
 Date of Award: 2008
 Project Title: **Transforming care for mental illness and addiction – an integrated approach**
 Total Award: \$15,247,686
 PI: CAMH (M. Bagby, J. Cairney, T. George, L. Glicksman, S. Houle, J. Kennedy, J. Meyer, B. Mulsant, J. Rehm, G. Remington)

Name of Agency: Medicure Inc.
 Date of Award: 2009-2010
 Project Title: **5'-phosphate-monohydrate in the treatment of tardive dyskinesia**
 Total Award: \$272,505
 PI: Gary Remington

Name of Agency: Schizophrenia Society of Ontario
 Date of Award: 2009-2011
 Project Title: **Evaluation of motivational deficits in schizophrenia in a virtual environment: development of an ecologically valid assessment tool**
 Total Award: \$50,000
 PI: Gary Remington
 Co-I: G. Foussias, K. Zakzanis

Name of Agency: Neurocrine Biosciences, Inc.
 Date of Award: 2010-2011
 Project Title: **A Phase 2 open-label, dose titration study to evaluate the efficacy and safety of NBI-98854 for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder**
 Total Award: 192,463
 PI: Gary Remington
 Co-I: Ofer Agid, George Foussias, M Hahn

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2011-2012
 Project Title: **Patterns of antipsychotic nonadherence: impact on treatment outcome**
 Total Award: 192,539
 PI: Gary Remington
 Co-I: Tony George, David Streiner, George Foussias, Ofer Agid, Margaret

Hahn

Name of Agency: CAMH AFP
 Date of Award: April 2011-March 2012
 Project Title: **A treatment algorithm for refractory and ultraresistant schizophrenia**
 Total Award: 51,853
 PI: Gary Remington
 Co-I: Tony George, Jeff Daskalakis, Ofer Agid, George Foussias, Margaret Hahn

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 04.2014-03.2018
 Title: **Clozapine levels, clinical response, and side effects**
 Total Award: 442,650
 PI: Gary Remington
 Co-I: B. Pollock, D. Streiner, R. Wennberg, D. Mueller, T. Rajji, Ofer Agid, S. Kidd, G Foussias, G. Fervaha, H. Takeuchi, J. Lee

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award:
 Title: **The role of glutathione in glutamatergic system dysregulation in treatment-resistant schizophrenia**
 Total Award: 787,713
 PI: Ariel Graff, Gary Remington
 Co-I: Sofia Chavez, Vincenzo De Luca, Philip Gerretsen, Shinichiro Nakajima

Co-Investigator

Name of Agency: Eli Lilly Canada Inc.
 Date of Award: 1996-1997
 Project Title: **An open label study assessing the *in vivo* 5-HT₂ and D₂ receptor occupancy of olanzapine using PET in patients with schizophrenia**
 Total Award: \$178,000
 PI: S. Kapur
 Co-Investigators: G. Remington, R. B. Zipursky, P. Roy, S. Houle

Name of Agency: Wyeth Ayerst Canada Inc.
 Date of Award: 1996-1997
 Project Title: **Combining loxapine and cyproheptadine for unique clozapine-like 5-HT₂ and D₂ profile**
 Total Award: \$34,500
 PI: S. Kapur
 Co-Investigators: R. B. Zipursky, G. Remington, S. Houle

Name of Agency: Canadian Psychiatric Research Foundation (CPRF)
 Date of Award: 1997-1998

Project Title: **Amoxapine as an atypical antipsychotic: a PET analysis**
 Total Award: \$30,000
 PI: S. Kapur
 Co-Investigators: R. B. Zipursky, G. Remington

Name of Agency: Eli Lilly Canada Inc.
 Date of Award: 1997-1999
 Project Title: **Acute and long-term efficacy of olanzapine in first-episode psychotic disorders: a randomized double-blind comparison with haloperidol**
 Total Award: \$1,742,050
 PI: R. B. Zipursky
 Co-Investigators: S. Kapur, B. Christensen, P. Roy, G. Remington, D. Mikulis, A. Damyanovich, J. Daskalakis, I. Epstein

Name of Agency: Eli Lilly Canada Inc.
 Date of Award: 1997-1999
 Project Title: **A single site PET study to investigate the D₂ and 5-HT₂ occupancy of olanzapine and the relationship to clinical outcome**
 Total Award: \$360,950
 PI: R. B. Zipursky, S. Kapur
 Co-Investigators: B. Christensen, P. Roy, G. Remington, D. Mikulis, A. Damyanovich

Name of Agency: AstraZeneca Canada Inc.
 Date of Award: 1999
 Project Title: **Investigating the prolonged receptor effects of quetiapine: a PET study**
 PI: S. Kapur
 Co-Investigators: G. Remington, R. B. Zipursky

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2004 (1 year)
 Project Title: **Validation of a physical activity assessment tool for individuals with schizophrenia**
 Total Award: \$40,617
 PI: G. Faulkner
 Co-Investigators: T. Cohn, G. Remington

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2006 (4 years)
 Project Title: **Strategies for gene discovery in schizophrenia**
 Total Award: 120,683
 PI: J. Kennedy
 Co-investigators: F. Macciardi, G. Remington, A. Wong

Name of Agency: Canadian Psychiatric Research Foundation (CPRF)
 Date of Award: 2006 (2 years)

Project Title: **Antipsychotic polypharmacy in schizophrenia**
 Total Award: 80,000
 PI: D. Mamo
 Co-investigators: Bruce Christensen, Jeff Daskalakis, Gary Remington, Albert Wong, Robert Zipursky

Name of Agency: Schizophrenia Society of Ontario
 Date of Award: 2007 (2 years)
 Project Title: **Randomized, controlled trial of cognitive behaviour therapy in early psychosis**
 Total Award: 100,000
 PI: J. Addington
 Co-investigators: Bruce Christensen, Gary Remington, Mahesh Menon, Georges Monette

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2008-2013 (5 years)
 Project Title: **Genetics of antipsychotic-induced weight gain**
 Total Award: 807,430
 PI: D. Mueller
 Co-investigators: Kennedy JL, Remington G, Cohn T, Tilvari AK

Name of Agency: Pfizer Canada Inc.
 Date of Award: 2008-2010
 Project Title: **24-hour time course of striatal dopamine D₂ receptor occupancy of ziprasidone: a PET study**
 Total Award: 331,155 (2 years)
 PI: David Mamo
 Co-investigators: Uchida H, Ismail Z, Mulsant B, Pollock P, Remington G

Date of Award: 2010-2012
 Project Title: **Transcranial magnetic stimulation to evaluate the role of clozapine potentiation of GABA in the treatment of schizophrenia**
 Total Award: 141,700 (2 years)
 PI: Jeff Daskalakis
 Co-investigators: Gary Remington, Ofer Agid, Albert Wong

Name of Agency: CAMH AFP
 Date of Award: 2011-2013
 Project Title: **Electronic metabolic monitoring for patients on atypical antipsychotics: a multi-site knowledge translation and diabetes prevention project**
 Total Award: 99,472 (2 years)
 PI: Tony Cohn
 Co-investigators: Gary Remington, Margaret Hahn, Guy Faulkner, Shannon Grant,

Ranjith Chandrasena, Howard Barbaree, Jacqueline Duncan

Name of Agency: CAMH AFP
 Date of Award: 2011-2013
 Project Title: **Functional assessment and treatment planning for schizophrenia in a virtual reality environment**
 Total Award: 105,000
 PI: Albert Wong
 Co-investigators: Gary Remington, George Fousias

Name of Agency: Ontario Shores Pilot Research Fund
 Date of Award: 2011-2012
 Project Title: **Evaluating monitoring practices for movement disorders in patients on antipsychotics**
 Total Award: 7,000
 PI: Jamie Kellar
 Co-investigators: Gary Remington, Beth Sproule, Caroline Warnock

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2011-2016
 Project Title: **Strategies for gene discovery in schizophrenia: subphenotypes, deep sequencing, and interactions**
 Total Award: 791,150
 PI: James Kennedy
 Co-investigators: Vincenzo De Luca, Arun Tiwari, Clement Zai, Daniel Mueller, Aristotle Voineskos, Gary Remington, Albert Wong

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2011-2013
 Project Title: **Imaging the limbic dopamine D₃ receptor in schizophrenia**
 Total Award: 209,150
 PI: Ariel Graff, David Mamo
 Co-Investigators: Agid O, Menon M, Remington G, Houle S

Name of Agency: Schizophrenia Society of Ontario
 Date of Award: 2011-2013
 Project Title: **Deep brain stimulation for the management of treatment refractory primary negative symptoms in schizophrenia**
 Total Award: 100,000
 PI: Jeff Daskalakis
 Co-Investigators: Lozano AM, Fousias G, Remington G, Voineskos A, Hamani C, Daskalakis ZJ

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2012-2015

Project Title: **Identifying and measuring correlates and determinants of physical activity in individuals with schizophrenia**
 Total Award: 200,000
 PI: Guy Faulkner
 Co-Investigators: Arbour-Nicitopoulos KP, Cairney J, Cohn TA, Remington G, Stone M

Name of Agency: Canadian Diabetes Association (CDA)
 Date of Award: 2012-2015
 Project Title: **Lifestyle interventions for the prevention and management of diabetes in schizophrenia**
 Total Award: 294,505
 PI: Rohan Ganguli
 Co-Investigators: Remington G, Faulkner G, Wolever T

Name of Agency: Ontario Mental Health Foundation (OMHF)
 Date of Award: 2013-2015
 Project Title: **Dissecting the heterogeneity of schizophrenia: biomarker discovery for primary negative symptoms**
 Total Award: 123,136
 PI: Aristotle Voineskos
 Co-Investigators: Zakzanis K, Remington G, Foussias G, Lerch J

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award: 2013-2017
 Project Title: **Stress-induced dopamine release in subjects at clinically high risk for psychosis: a [¹¹C]-FBL457 PET study**
 Amount: 363,973
 PI: Romina Mizrahi
 Co-Investigators: Houle S, Kenk M, Remington G, Rusjan P, Wilson A

Name of Agency: CARSTAR Automotive Canada Research Innovation Fund
 Date of Award: 08.2013-07.2015
 Project Title: **A personalized medicine approach to the long-term treatment of schizophrenia**
 Amount: 32,000
 PI: Robert Zipursky
 Co-Investigators: Kiang M, Cook P, Agid O, Remington G, Streiner D

Name of Agency: Ontario Mental Health Foundation (OMHF)
 Date of Award: 04.2014-03.2016
 Project Title: **Deconstructing motivational deficits in schizophrenia and depression**
 Amount: 149,940
 PI: George Foussias
 Co-Investigators: Remington G, Ravindran A, Zakzanis K

Name of Agency: National Institute of Health (US)
 Date of Award: 07.16.14-04.30.19
 Project title: **Social processes initiative in the neurobiology of the schizophrenia(s)**
 Amount: 4,877,390
 PI: Aristotle Voineskos, Anil Malhotra, Robert Buchanan, Will Carpenter
 Co-Investigators: George Foussias, Jim Gold, Gary Remington, Gregory Strauss, Philip Szeszko

Name of Agency: Hotchkiss Brain Institute/Matheson Centre for Mental Health Research and Education Seed Grant
 Date of Award: 01.01.15-12.31.15
 Project Title: **Canadian clinical practice guidelines for the treatment of schizophrenia and other psychotic disorders**
 Amount: 40,452
 PI: Donald Addington, Tamara Pringsheim
 Co-Investigators: Jean Addington, Zahinoor Ismail, Ross Norman, Gary Remington

Name of Agency: National Institute of Health (US)
 Date of Award: 01.01.14-12.31.18
 Project Title: **Imaging neuroinflammation in clinical high risk and schizophrenia**
 Amount: 1,312,692
 PI: Romina Mizrahi
 Co-Investigators: Houle S, Kenk M, Remington G, Rusjan P, Wilson A

Name of Agency: Ontario Mental Health Foundation
 Date of Award: 02.01.15-01.31.17
 Project Title: **The role of glutathione in glutamatergic system dysregulation in treatment-resistant schizophrenia**
 Amount: 74,769
 PI: Ariel Graff-Guerrero
 Co-Investigators: Gary Remington, Phil Gerretsen, Shinichiro Nakajima, Vincenzo DeLuca, Napapon Sailusta, Mallar Chakravarty

Name of Agency: Canadian Institutes of Health Research (CIHR)
 Date of Award:
 Project Title: **Development, validation and benefits of a genetic risk model for antipsychotic-induced weight gain**
 Amount: 704,869
 PI: Daniel Mueller
 Co-Investigators: Ana Andreazza, Vanessa Goncalves, Margaret Hahn, James Kennedy, Gary Remington, Arun Tiwari, Clement Zai

D. Presentations and Special Lectures

D.1. Conference Posters and Presentations

1. Remington G, Sklar LS, Anisman H. Effects of inescapable shock on subsequent escape performance: dopaminergic mediation of response initiation and maintenance. Canadian Psychological Association, Vancouver, British Columbia, June 1977
2. Sklar LS, Remington G, Anisman H. Effects of inescapable shock on subsequent escape performance: effects of catecholaminergic manipulations. Canadian Psychological Association, Vancouver, British Columbia, June 1977
3. Remington G, Hoffman B. Gas sniffing as a form of a substance abuse. Canadian Psychiatric Association 32nd Annual Meeting, Montreal, Quebec, September 1982
4. Remington G, Jeffries JJ. Psychiatric disturbances associated with cerebral arteriovenous malformations. Canadian Psychiatric Association 32nd Annual Meeting, Montreal, Quebec, September 1982
5. Jeffries JJ, Remington G, Wilkins J. Combined lithium/neuroleptic toxicity. Canadian Psychiatric Association 32nd Annual Meeting, Montreal, Quebec, September 1982
6. Seeman M, Voineskos G, Remington G, Tourgis P, Goering P. Schizophrenia: comprehensive continuing care. Ontario Psychiatric Association 64th Annual Meeting, Toronto, Ontario, January 1984
7. Remington G, Book H. De Clerambault's syndrome, bipolar affective disorder and response to lithium. Canadian Psychiatric Association 36th Annual Meeting, Banff, Alberta, October 1984
8. Menuck M, Remington G, Schmidt P, Legault S. Classification of functional psychoses. Ontario Psychiatric Association 65th Annual Meeting, Toronto, Ontario, January 1985
9. Rosenblat R, Tang S, Persad E, Remington G. Propranolol-antidepressant interaction. Clinical Research Society of Toronto, Toronto, Ontario, April 1985
10. Remington G, Legault S, Schmidt P, Menuck M. The nosologic status of the atypical functional psychoses. I. A clinical profile of the atypical psychoses. Conference of the World Psychiatric Association on Nomenclature and Classification, Montreal, Quebec, June 1985
11. Schmidt P, Legault S, Remington G, Menuck M. The nosologic status of the atypical functional psychoses II. Conference of the World Psychiatric Association on Nomenclature and Classification, Montreal, Quebec, June 1985
12. Legault S, Schmidt P, Remington G, Menuck M. The nosologic status of the atypical psychoses III. 'Cycloid psychosis' and the atypical functional psychoses. Conference of the World Psychiatric Association on Nomenclature and Classification, Montreal, Quebec, June 1985
13. Remington G. Neuroleptics: emergency use and current research. Conference on Practical Issues in Clinical Psychopharmacology, Toronto, Ontario, November 1985
14. Persad E, Remington G. New approaches in the pharmacotherapy of mania and depression. Ontario Psychiatric Association 66th annual Meeting, Toronto, Ontario, January 1986
15. Remington G, Pollock B, Voineskos G, Warsh J, Reed K, Beresford J, Coulter K. The emergency treatment of acutely psychotic patients: clinical and pharmacologic correlates. Fourth World Congress of Biological Psychiatry, Philadelphia, Pennsylvania, September 1986
16. Remington G, Book H. Discriminative validity of the Borderline Syndrome Index, a self-report questionnaire. Canadian Psychiatric Association 38th Annual Meeting, Vancouver, British Columbia, September 1986

17. Jeffries JJ, Remington G. Schizophrenia and depression. Conference on Affective Disorders: New Approaches to Investigation and Management, Toronto, Ontario, November 1988
18. Prendergast P, Turner T, Remington G. High dose, low dose, no dose - the role of medication in chronic schizophrenia. Psychiatric Rehabilitation: A National Perspective Conference, Toronto, Ontario, October 1989
19. Remington G. Symposium Chair, New perspectives in the pharmacological treatment of schizophrenic patients: role of zuclopenthixol. Schizophrenia 1990: Poised for Discovery, an International Conference, Vancouver, British Columbia, July 1990
20. Remington G, Voineskos G, Pollock B, Reed K, Coulter K, Acutely psychotic patients receiving high dose neuroleptic therapy. Schizophrenia 1990: Poised for Discovery, an International Conference, Vancouver, British Columbia, July 1990
21. Remington G, Fornazzari L, Tupling S, Rosenblat H, Coulter K, Hassell K. The quantitative assessment of akathisia. Schizophrenia 1990: Poised for Discovery, an International Conference, Vancouver, British Columbia, July 1990
22. Prendergast P, Turner T, Remington G. High dose, low dose, no dose - the role of medication in chronic schizophrenia. Canadian Psychiatric Association 40th Annual Meeting, Toronto, Ontario, September 1990
23. Fornazzari L, Remington G, Collins A, Rosenblat H, Smith I, Hassell K, Coulter K, Jeffries JJ. Dysprosodias in schizophrenia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990
24. Remington G, Fornazzari L, Tupling S, Rosenblat H, Coulter K, Hassell K. The quantitative assessment of akathisia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990
25. Remington G, Voineskos G, Pollock B, Reed K, Coulter K. Incidence of neuroleptic-induced dystonia in mania versus schizophrenia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990
26. Prendergast P, Remington G, Bezchlibnyk-Butler K. Neuroleptic dosing patterns in chronic schizophrenia. Canadian Psychiatric Association 40th annual Meeting, Toronto, Ontario, September 1990
27. Awad G, Cleghorn J, Schulz C, Remington G. Drug therapy in schizophrenia - variability of outcome and prediction of response. Canadian College of Neuropsychopharmacology XIV Annual Meeting, Hamilton, Ontario, June 1991
28. Chouinard G, Burns H, Remington G, Gauthier S. Assessment of drug-induced EPS. Canadian College of Neuropsychopharmacology XIV Annual Meeting, Hamilton, Ontario, June 1991
29. Fornazzari L, Remington G, Collins P, Rosenblat H, Coulter K, Smith I, Birkett K, Jeffries JJ. Impairment of emotionality in schizophrenia, a non-verbal and paralinguistic deficit in non-dominant hemisphere, Canadian College of Neuropsychopharmacology XIV Annual Meeting, Hamilton, Ontario, June 1991
30. MacEwan GW, Ancill RJ, Remington G, Jones B. Symposium on the treatment resistant psychotic patient. Canadian Psychiatric Association 41st Annual Meeting, Saskatoon, Saskatchewan, October 1991
31. Chouinard G, Jones B, Remington G, Addington D, Nair NPV, MacEwan GW. A placebo-controlled study of risperidone in the treatment of schizophrenia. American College of Neuropsychopharmacology 30th Annual Meeting, San Juan, Puerto Rico, December 1991

32. Jeffries JJ, del Rosario J, Remington G. Carbamazepine for schizophrenia. Ontario Psychiatric Association 72nd Annual Meeting, Toronto, Ontario, January 1992
33. Chouinard G, Jones B, Remington G, Addington D, Nair NPV, MacEwan GW. A placebo-controlled study of risperidone in the treatment of schizophrenia. 145th Annual Meeting of the American Psychiatric Association, Washington, D.C., May 1992
34. Remington G. Acute pharmacologic management: historical perspective and current guidelines - a role for zuclopenthixol. Schizophrenia 1992: Poised for Change, Vancouver, British Columbia, July 1992
35. Baskys A, Remington G, Wang S, Wojtowicz JM. Atypical neuroleptic clozapine blocks synaptic transmission in the hippocampus. Schizophrenia 1992: Poised for Change, Vancouver, British Columbia, July 1992
36. MacEwan GW, Chouinard G, Jones B, Remington G, Addington D, Nair NPV, Arnott W. A Canadian multicentre fixed-dose study of risperidone in chronic schizophrenia. Schizophrenia 1992: Poised for Change, Vancouver, British Columbia, July 1992
37. Remington G, Yassa R, Shriqui C, Chouinard C. Neuroleptic-induced movement disorders. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992
38. Jeffries JJ, Del Rosario J, Remington G, Williams R. Carbamazepine in schizophrenia. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992
39. Schacter DC, Kleinman I, Prendergast P, Remington G, Schertzer S. The effect of psychopathology on schizophrenic patients' ability to give informed consent. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992
40. Chouinard C, Bloom D, Beauclair L, Jones B, Labelle A, Remington G, Addington D, MacEwan G, Arnott W. A Canadian multicentre placebo-controlled study of risperidone and haloperidol in chronic schizophrenic patients. Canadian Psychiatric Association 42nd Annual Meeting, Montreal, Quebec, September 1992
41. Baskys A, Remington G, Palmer E, Wojtowicz JM. Effects of clozapine (cloz), loxapine (lox) and haloperidol (hal) on synaptic transmission in the CA₁ area of the hippocampus. Society for Neuroscience 22nd Annual Meeting, Anaheim, California, October 1992
42. Collins E, Remington G, Jones B. Assessment and treatment of extrapyramidal symptoms of schizophrenia: a workshop for clinicians. Ontario Psychiatric Association 73rd Annual Meeting, Toronto, Ontario, January 1993
43. Baskys A, Wang S, Remington G, Wojtowicz JM. Haloperidol and loxapine but not clozapine increase synaptic responses in the CA₁ area of the rat hippocampus *in vitro*. 13th European Winter Conference on Brain Research. La Plagne, France, March 1993
44. Remington G, Reed K, Voineskos G, Coulter K. A double-blind comparison of zuclopenthixol acetate and haloperidol in acutely psychotic patients. The IVth International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 1993
45. Remington G, Pollock B, Reed K, Coulter K, Voineskos G. Plasma neuroleptic levels in patients with and without acute dystonic reactions. The IVth International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 1993
46. Jones B, Addington DE, Bloom D, Chouinard G, Remington G. Risperidone in chronic schizophrenia: impact on health care systems costs. 9th World Congress of Psychiatry, Rio de Janeiro, Brazil, June 1993

47. Jones B, Collins E, Remington G, MacEwan W, Lieberman JA, Defining the treatment refractory schizophrenic patient. Canadian Psychiatric Association 43rd Annual Meeting, Winnipeg, Manitoba, September 1993
48. Addington DE, Bloom D, Chouinard G, Jones B, Remington G. The effect of risperidone on hospitalization in chronic schizophrenia. Canadian Psychiatric Association 43rd Annual Meeting, Winnipeg, Manitoba, September 1993
49. Chouinard G, Addington D, Bloom D, Jones B, Remington G, Albright P. Economic health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hawaii, December 1993
50. Remington G, Jeffries J, Papatheodorou G, Goldberg J. Moderator, symposium "What's new in schizophrenia: a clinical update". Ontario Psychiatric Association 74th Annual Meeting, Toronto, Ontario, January 1994
51. Remington G. New and alternative drug treatments. Schizophrenia: recent progress and perspectives. Symposium presented at the Canadian College of Neuropsychopharmacology 17th Annual Meeting (CINP), Quebec City, Quebec, June 1994
52. Remington G, Prendergast P, Bezchlibnyk-Butler K. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994
53. Remington G. The impact of balanced serotonin-dopamine antagonism on the incidence of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD). Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994
54. Remington G. Acute treatment of psychosis. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994
55. Remington G, Collins A, Coulter K, Birkett K, Smith I. Neuropsychology of unawareness of illness in chronic schizophrenia. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994
56. Collins A, Remington G, Coulter K, Birkett K, Smith I. Insight and symptom clusters in chronic schizophrenia. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 1994
57. Remington G, Collins A, Coulter K, Birkett K, Smith I. Depression and negative symptoms in chronic schizophrenia. Canadian Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 1994
58. Collins A, Remington G, Coulter K, Birkett K, Smith I. Insight and schizophrenia. Canadian Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 1994
59. Smith I, Remington G, Collins A, Coulter K, Birkett K. Neuropsychological impairment in chronic schizophrenia. Canadian Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 1994
60. Al-Jeshi A, Kapur S, Remington G, Jeffries J. Is loxapine the best available antipsychotic. Ontario Psychiatric Association 75th Annual Meeting, Toronto, Ontario, January 1995
61. Tugg L, Prendergast P, Remington G, Zipursky R. Maintenance neuroleptics in chronic schizophrenia. Ontario Psychiatric Association 75th Annual Meeting, Toronto, Ontario, January 1995
62. Zaharia MD, Ravindran AV, Griffiths J, Remington GJ, Merali Z, Anisman H. Laboratory and naturalistic stressors influence immune functioning. Society for Neuroscience 25th Annual Meeting, San Diego, California, November 1995

63. Malla A, Teehan M, Remington G. Risperidone: from clinical research to clinical practice. Ontario Psychiatric Association 76th Annual Meeting, Toronto, Ontario, January 1996
64. Remington G, Kapur S, Zipursky RB. Neuroleptic dosing and clinical correlates in first-episode psychosis: application of PET. *Verging on Reality: The 1st International Conference on Strategies for Prevention of Early Psychosis*. Melbourne, Australia, June 28-29, 1996
65. Remington G, Kapur S, Zipursky R. Pharmacotherapy of first episode psychosis. Symposium, *Preventive Strategies in Early Psychosis Xth World Congress of Psychiatry*, Madrid, Spain, August 23-28, 1996
66. Remington G, Prendergast P, Tugg L, Reed K, Zipursky R. Maintenance neuroleptic therapy: plasma and clinical correlates. Xth World Congress of Psychiatry, Madrid, Spain, August 23-28, 1996
67. Remington G. Novel neuroleptics, mechanisms of action, and clinical implications. Symposium, *First Episode Psychosis: Treatment and Outcome*. Canadian Psychiatric Association 46th Annual Meeting, Quebec City, Quebec, October 1996
68. Remington G. First episode psychosis: integrating PET and clinical data. *First Episode Psychosis: an Interactive Workshop*, Schizophrenia 1996 Conference, Vancouver, British Columbia, October 1996
69. Collins A, Remington G, Coulter K, Birkett K. Insight and symptom clusters in schizophrenia. Schizophrenia 1996 Conference, Vancouver, British Columbia, October 1996
70. Remington G. New horizons for schizophrenic patients. Symposium, *New Horizons in Psychosis*. 7th International Pan Arab Conference of Psychiatry, Beirut, Lebanon, November 1996
71. Kapur S, Remington G, Jones C, Houle S, Zipursky R. 'Typical' vs 'atypical': lessons from PET studies of 5-HT₂ and D₂ occupancy of antipsychotics. The VIth International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 1997
72. Kapur S, Remington G, Houle S, Zipursky RB. A new classification of antipsychotics based on 5-HT₂/D₂ receptor imaging. American Psychiatric Association 150th Annual Meeting, San Diego, California, May 1997
73. Kapur S, Jones C, Remington G, Houle S, Zipursky RB. Does loxapine plus cyproheptadine make clozapine: evidence from PET imaging. 6th World Congress of Biological Psychiatry, Nice, France, June 1997
74. Remington G, Teehan M, Beauséjour P. Schizophrenia: early detection, assessment, pharmacologic treatment and rehabilitation. Canadian Psychiatric Association 47th Annual Meeting, Calgary, Alberta, September 1997
75. Remington G. Chronic schizophrenia: issues in pharmacotherapy. Symposium, *Psychosis Through the Life Span: Integrating Theory and Clinical Practice*. Canadian Psychiatric Association 47th Annual Meeting, Calgary, Alberta, September 1997
76. Remington G. Clinical issues in treatment-resistant schizophrenia. Symposium, *New Considerations in the Diagnosis and Management of Treatment-Resistant Schizophrenia*. Canadian Psychiatric Association 47th Annual Meeting, Calgary, Alberta, September 1997
77. Remington G, Teehan M, Lalonde P. Schizophrenia: early detection, assessment, pharmacologic treatment, and rehabilitation. Hôpital Louis-H. Lafontaine, Montreal, Quebec, October 31, 1997

78. Remington G, Teehan M. Decision-making in the pharmacotherapy of schizophrenia. A Patient-Based Learning Program for the Management of Schizophrenia and Related Psychotic Disorders. Montreal, Quebec, November 15, 1997
79. Kapur S, Cho R, Jones C and the Schizophrenia PET Group. Is amoxapine an atypical antipsychotic? Suggestive evidence from PET investigations of 5-HT₂ and D₂ receptor occupancy. American College of Neuropsychopharmacology 36th Annual Meeting, Wiakola, Hawaii, December 8-12, 1997
80. Zipursky R, Remington G and the Schizophrenia PET Group. PET investigation of olanzapine effects on 5-HT₂ and D₂ receptors in patients with schizophrenia. American College of Neuropsychopharmacology 36th Annual Meeting, Wiakola, Hawaii, December 8-12, 1997
81. Zipursky R, Kapur S, Jones C, Remington G, Shammi C, Houle S. Is there a “glass ceiling” to the D₂ occupancy of clozapine? American College of Neuropsychopharmacology 36th Annual Meeting, Waikola, Hawaii, December 1997
82. Remington G. Symposium Chair, Schizophrenia: What is an Acceptable Outcome in 1998? With Drs. M. Seeman, L. Cortese. Ontario Psychiatric Association Annual Meeting, Toronto, January 21-24, 1998
83. Ungar T, Remington G, Keith R. ACCESS: a national program of education and consultation in psychiatry. American Association of Continuing Medical Education, San Diego, California, January 29, 1998
84. Remington G. Symposium Chair, PET Studies in Schizophrenia: Clinical Implications. With Dr. S. Kapur. Ontario Psychiatric Association Annual Meeting, Toronto, January 21-24, 1998
85. Remington G, Jeffries JJ. Treatment considerations. Workshop presented at Schizophrenia Update '98, Scottsdale, Arizona, March 25-28, 1998
86. Remington G. New treatment options and decision-making. A Patient-Based Learning Program for the Management of Schizophrenia and Related Psychotic Disorders. Niagara-on-the-Lake, Ontario, April 25, 1998
87. Kapur S, Zipursky RB, Jones C, Remington G, Houle S. The receptor occupancy of olanzapine assessed with PET: theoretical and clinical implications. Annual Meeting of the Society of Biological Psychiatry, Toronto, Ontario, June 1998
88. Sloman L, Remington G, Konstantareas M, Parker K. Haloperidol versus clomipramine in autistic disorders. American Psychiatric Association 151st Annual Meeting, Toronto, Ontario, May 30-June 4, 1998
89. Kapur S, Lewis R, Remington G, Zipursky R. PET studies of 5-HT₂ receptors in schizophrenia: implications for etiology and therapeutics. 21st Annual Meeting of the Canadian College of Neuropsychopharmacology, Montreal, Quebec, June 1998
90. Remington G. Schizophrenia and neuroleptics: ethical and medicolegal issues. XXIIrd International Congress on Law and Mental Health, Paris, France, July 1-3, 1998
91. Anand R, Alphs L, Azorin JM, Remington G, Péré J-J, Bourdeix I. Superior efficacy of clozapine in chronic, severe schizophrenia: comparison with risperidone. Treatment-Resistant Schizophrenia and Beyond. London, England, July 8-9, 1998
92. Remington G. From the lab to clinical practice: what are the clinical implications? Symposium, Integrating Science with Clinical Practice to Optimize Outcome in Schizophrenia. Canadian Psychiatric Association 48th Annual Meeting. Halifax, Nova Scotia, September 1998

93. Remington G. Practical guidelines in the use of neuroleptics. First Episode Psychosis VI: Onset, Diagnosis, Management. Centre for Addiction and Mental Health, Clarke Site, Toronto, Ontario, October 30, 1998
94. Remington G. From the lab to clinical practice: what are the clinical implications? Symposium, Integrating Science with Clinical Practice to Optimize Outcome in Schizophrenia. Schizophrenia 1998: Reintegration in a Climate of Restraint. Toronto, Ontario, November 1998
95. Remington G. Novel antipsychotics: integrating PET data and clinical use. Symposium, Heterogeneity of Novel Antipsychotics: Implications for the Clinician. Schizophrenia 1998: Reintegration in a Climate of Restraint. Toronto, Ontario, November 1998
96. McGorry P, Remington G. Early intervention in psychosis. CNS Challenge – Beyond 2000. Barcelona, Spain, April 1999
97. Remington G. Serotonin/dopamine antagonism and atypicality: *in vivo* evidence using PET. Symposium: What Makes an Antipsychotic Atypical? The 152nd Annual Meeting of the American Psychiatric Association, Washington DC, May 1999 (Syllabus No. 25B, p 252)
98. Kapur S, Jones C, Seeman P, Remington G, Zipursky R. Prolonged receptor occupancy after a single dose of antipsychotics – do we really need to give these drugs everyday? American College of Neuropsychopharmacology 38th Annual Meeting, Acapulco, Mexico, December 12-16, 1999 (Syllabus No. 105, p 143)
99. Addington DE, Addington JM, Patten SB, Remington GJ, Moamai J, Labelle A, Beauclair L. Sertraline for depression in remitted schizophrenia. American Psychiatric Association, 153rd Annual Meeting, Chicago, Illinois, May 13-18, 2000
100. Remington G. Antipsychotics: integrating theory and clinical practice. Symposium Psychopharmacologie, 34^e Congrès Annuel de l'AMPQ, Quebec City, Quebec, May 25-27, 2000
101. Kapur S, Wadenber M-L, Remington G, Zipursky R, Houle S. Dopamine D2 occupancy as a linking variable between animal and clinical studies of antipsychotic drugs. The 3rd International Symposium on Functional Neuroreceptor Mapping, Columbia University, New York, NY, June 2000
102. Addington D, Beauclair L, Labelle A, Moamai J, Patten S, Remington G. A double-blind, placebo-controlled comparison of sertraline for major depression in patients with remitted schizophrenia. 50th Annual Meeting of the Canadian Psychiatric Association, Victoria, British Columbia, October 3-6, 2000
103. Remington G. Antipsychotic dosing patterns in 3 treatment settings. Schizophrenia Clinical Update 2000, Toronto, Ontario, October 25-27, 2000
104. Remington G, Cohn T. Antipsychotic-related side effects. Schizophrenia Clinical Update 2000, Toronto, Ontario, October 25-27, 2000
105. Dewa CS, Remington G, Fearnley J, Goering P. A preliminary examination of trends in the use of new antipsychotic agents. Annual Meeting of the American Public Health Association, Boston, Massachusetts, November 2000
106. Cohn TA, Remington GJ, Lieter L, Kameh H. Antipsychotic medication and insulin resistance. VIIIth International Congress on Schizophrenia Research, Whistler, British Columbia, Canada, April 28-May 2, 2001
107. Kapur S, Zipursky RB, Remington GJ. What really is “atypical” about atypical antipsychotics: lessons from PET imaging studies. Symposium, Atypical Antipsychotic Drugs: How Do They Work? 154th Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana, May 5-10, 2001

108. Cohn T, Remington GJ, Leiter L, Kameh H. Antipsychotic medication and insulin resistance. 154th Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana, May 5-10, 2001
109. Addington D, Patten S, Remington GJ, Moamai J. Sertraline for depression in remitted schizophrenia. 7th World Congress of Biological Psychiatry, Berlin, Germany, July 1-6, 2001
110. Remington G, Collins A. Video Workshop - An educational intervention to enhance compliance in schizophrenia. 53rd Institute on Psychiatric Services, American Psychiatric Association, Orlando, Florida, October 10-14, 2001
111. Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA, and the Canadian Switch Study Group. Switching from previous antipsychotics to olanzapine: memory and executive functions in an 8-week study. 51st Annual Canadian Psychiatric Association Meeting, Montreal, Quebec, November 15-19, 2001
112. Meltzer H, Kane JM, Remington G, Gaebel W, Lieberman J. How much of an advance are atypicals? Neuroscience Forum, Lisbon, Portugal, April 27-30, 2002
113. Dickson R, Violata C, Smekal T, Glazer WM, Remington GJ, Stip S, Walker D, Jones B. Serial measurement of sexual function using the DGSFi in an olanzapine switch trial. 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, May, 2002
114. Stip E, Remington GJ, Durson SM, Reiss JP, MacEwan GW, Chokka PR, Dickson RA, Jones B. Canadian multi-center trial assessing memory and executive function in patients with schizophrenia spectrum disorders treated with olanzapine. 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, May, 2002
115. Remington G, Devos E, Eerdeken , Duchesne I, Leaf A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use. XII World Congress of Psychiatry, Yokohama, Japan, August 24-29, 2002
116. Dickson R, Violata C, Smekal T, Glazer WM, Remington GJ, Stip S, Luther MF, Walker DJ, Jones B. Serial measurement of sexual function and prolactin levels in an olanzapine switch trial. 15th European College of Neuropsychopharmacology, Barcelona, Spain, October 5-9, 2002
117. Cohn T, Remington G. Cigarette smoking and diabetes in schizophrenia: evidence for an inverse correlation. IXth International Congress on Schizophrenia Research, Colorado Springs, Colorado, March 29-April 2, 2003
118. Remington G, Mamo D, Shammi C, Papatheodorou G, Mann S, Kapur S. Ziprasidone: D₂ and 5-HT₂ profile using PET. 156th Annual Meeting of the American Psychiatric Association, San Francisco, California, May 17-22, 2003
119. Mamo D, Hussey D, Chirakal R, Wilson A, Remington G, Nobrega J, Houle S, Kapur S. The effect of single-dose risperidone on dopamine synthesis in healthy human subjects measured using 6-[¹⁸F]-L-m-tyrosine positron emission tomography. Brain & PET 2003 Conference, Calgary, Alberta, July 2003
120. Remington G, Devos E, Eerdeken , Duchesne I, Leaf A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use. European Congress of Neuropsychopharmacology (ECNP), Prague, Czech Republic, September 20-24, 2003
121. Remington G, Mamo D, Shammi C, Papatheodorou G, Mann S, Kapur S. The 5-HT₂ and D₃ binding profile of Ziprasidone using PET: theoretical and clinical implications. 53rd Annual Meeting of the Canadian Psychiatric Association, Halifax, Nova Scotia, October 30-November 2, 2003

122. Remington G. Does serotonin have a role to play in antipsychotic 'atypicality'. Symposium, Serotonin Function: Andy Greenshaw (chair), Paul Fletcher, Pierre Blier, Gary Remington. 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, June 1, 2004
123. Remington G. Optimizing the maintenance treatment of schizophrenia. Symposium (R. Emsley, G. Remington, J. Volavka, M. Davidson), Critical Clinical Issues in the Treatment of Schizophrenia. XXIVth CINP Congress, Paris, France, June 20-24, 2004
124. Remington G. D₂ and 5-HT₂ profile of typical and atypical antipsychotics: PET evidence. Symposium, Dopamine-Serotonin Interactions in Psychosis and Antipsychotic Drug Actions (F. Tarazi, P. B. Bymaster, A. Y. Deutch, G. Remington). 35th Annual Meeting of the American Society for Neurochemistry, New York, New York, August 14-18, 2004
125. Zai CC, Hwang R, de Luca V, King N, Zai GC, Remington G, Kennedy JL. Evidence for association between dopamine DRD2 receptor polymorphisms and tardive dyskinesia in Caucasian schizophrenic patients. The 4th Annual Pharmacogenetics in Psychiatry Meeting, New York, New York, April 15-16, 2005
126. Cohn TA, Bois D, Remington G. Topiramate added to clozapine: metabolic effects, antipsychotic augmentation, safety, and tolerability: a 12-week, open study. 158th Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 21-26, 2005
127. Cohn TA, Bois D, Remington G, Wolever T. First-episode and neuroleptic-free schizophrenia patients have reduced insulin sensitivity: a minimal model analysis. 158th Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 21-26, 2005
128. Zai CC, Hwang R, DeLuca V, Muller D, King D, Zai GC, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Association study of 12 markers across DRD₂ in tardive dyskinesia. XIIIth World Congress of Psychiatric Genetics, Boston Massachusetts, October 14-18, 2005
129. Remington G. Pharmacotherapy in the earliest stages of schizophrenia: too much too soon or too little too late. Symposium, Early Intervention in Schizophrenia: Biological and Psychosocial Approaches to Optimize Outcome (R Zipursky, O Agid, G Remington, A Collins, J Addington). 55th Annual Conference of the Canadian Psychiatric Association, Vancouver, British Columbia, November 3-6, 2005
130. Zai CC, De Luca V, Muller DJ, Remington G, Kennedy JL. Meta-analysis of two DRD2 polymorphisms and tardive dyskinesia in Caucasian and Asian schizophrenia patients. 5th Annual Pharmacogenetics in Psychiatry Meeting, New York, April 7-8, 2006
131. Zai CC, De Luca V, Muller D, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association of a polymorphism 5' of the dopamine receptor DRD3 gene in schizophrenic Caucasians with tardive dyskinesia. 11th Annual International Congress on Human Genetics, Brisbane, Australia, August 6-10, 2006
132. De Luca V, Zai C, Muller DJ, Lieberman J, Meltzer H, Remington G, Kennedy JL. Alternative strategies for quantitative trait haplotype analysis: application to MDR1 gene in tardive dyskinesia. World Psychiatric Genetics Congress XII. October 28-November 1, 2006
133. Zai CC, Romano-Silva MA, Hwang R, Zai GC, De Luca V, Muller D, Voineskos A, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. World Congress of Psychiatric Genetics XV, New York, New York, October 7-11, 2007
134. Faulkner G, Cohn T, Remington G. Behavioural interventions to reduce weight gain in

- schizophrenia. World Psychiatric Association (WPA) International Congress, Melbourne, Australia, November 28-December 2, 2007
135. Tiwari AK, Zai CC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Lack of association of the cannabinoid receptor (CNR1) gene to tardive dyskinesia in chronic schizophrenia patients. 7th Annual Pharmacogenetics in Psychiatry Meeting, New York, April 4-5, 2008
 136. Zai CC, De Luca V, Muller DJ, King N, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and five *DRD4* polymorphisms in schizophrenia patients. 7th Annual Pharmacogenetics in Psychiatry Meeting, New York, April 4-5, 2008
 137. . Motivation and pleasure in the schizophrenia spectrum: findings from the prodrome. Canadian Society for Clinical Investigation (CSCI)/Clinician Investigator Trainee Association of Canada (CITAC) Meeting, Toronto, Ontario, September 24-25, 2008
 138. Foussias G, Mann S, Remington G. A phenomenological study of negative symptoms in schizophrenia: amotivation and its relationship to functioning. American College of Neuropsychopharmacology (ACNP), 47th Annual Meeting, Scottsdale, Arizona, December 7-11, 2008
 139. Mizrahi R, Addington J, Rusjan P, Boileau I, Pruessner J, Ng A, Remington G, Houle S, Wilson AA. Stress-induced dopamine in subjects at clinical high risk for psychosis: a [¹¹C]-(+)-PHNO PET preliminary report. American College of Neuropsychopharmacology (ACNP), 47th Annual Meeting, Scottsdale, Arizona, December 7-11, 2008
 140. Remington G (Symposium Chair) Biological and structural factors mediating schizophrenia. 12th International Congress on Schizophrenia Research (ICOSR), San Diego, California, March 28-April 1, 2009
 141. Hirata Y, Souza RP, King N, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. RGS4 genes in schizophrenia: case-control and family-based studies, drug response and tardive dyskinesia. 59th Annual Meeting of the American Society of Human Genetics (ASHG), Honolulu, Hawaii, October 20-24, 2009
 142. Zai CC, Tiwari AK, De Luca V, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Genetic study of catechol-O-methyltransferase in tardive dyskinesia. XVII World Congress of Psychiatric Genetics, San Diego, California, November 4-8, 2009
 143. Potkin S, Agid O, Remington G, Kapur S, Watsky E, Vanderberg D, Siu C. Placebo response in antipsychotic trials: meta-regression and patient-level time course clustering analyses. American College of Neuropsychopharmacology (ACNP) 48th Annual Meeting, Hollywood, Florida, December 6-10, 2009
 144. Potkin SG, Agid O, Remington G, Kapur S, Watsky E, Vanderburg D, Siu CO. Placebo response in antipsychotic trials. International Society for CNS Clinical Trials and Methodology (ISCTM) 6th Annual Meeting, Washington, DC, February 22-24, 2010
 145. Zai CC, tiwari AK, Mueller DJ, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. The NMDA receptor gene Grin2B in tardive dyskinesia. 9th Annual Pharmacogenetics in Psychiatry Meeting, New York, NY, April 23-24, 2010
 146. Agid O, Potkin S, Remington G, Kapur S, Watsky E, Vanderburg D, Siu C. Meta-analysis of placebo response in antipsychotic trials. 163rd Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 22-26, 2010
 147. Gorczynski P, Faulkner G, Cohn T, Remington G. Using photovoice to facilitate formative research involving individuals with serious mental illness (SMI). Canadian

- Public Health Association Centenary Conference. Toronto, Ontario, June 13-16, 2010
148. Siu C, Agid O, Remington G, Kapur S, Watsky E, Vanderburg D, Potkin SG. Placebo response in antipsychotic trials. NCDEU 50th Annual Meeting, Boca Raton, FL, January 14-17, 2010
 149. Rajji T, Uchida H, Ismail Z, Ng W, Mamo D, Remington G, Pollock B, Mulsant B. Clozapine and global cognition in schizophrenia. NCDEU 50th Annual Meeting, Boca Raton, FL, January 14-17, 2010
 150. Foussias G, Mann S, Zakzanis K, van Reekum R, Agid O, Remington G. Motivational deficits in schizophrenia: cross-sectional and longitudinal relationships with functioning. 36th Annual Harvey Stancer Research Day, Toronto, Ontario, June 17, 2010
 151. Rajji T, Uchida H, Ismail Z, Ng W, Mamo D, Remington G, Pollock B, Mulsant B. Clozapine and global cognition in schizophrenia. 36th Annual Harvey Stancer Research Day, Toronto, Ontario, June 17, 2010
 152. Mizrahi R, Addington J, Rusjan P, Suridjan S, Boileau I, Ng A, Pruessner J, Remington G, Houle S, Wilson A. Stress-induced dopamine release in subjects at clinical high risk for psychosis and in antipsychotic-naïve patients with psychosis: a [¹¹C]-(+)-PHNO PET Study. 36th Annual Harvey Stancer Research Day, Toronto, Ontario, June 17, 2010
 153. Foussias G, Voineskos AN, Miranda D, Remington G, Rajji TK, Pollock BG, Mulsant BH, Kennedy JL. Oligodendrocyte gene polymorphisms and cognitive dysfunction in schizophrenia. 18th World Congress on Psychiatric Genetics, Athens, Greece, October 3-7, 2010
 154. Tiwari AK, Zai CC, Mueller DJ, Likhodi O, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Association study of cannabinoid receptor 1 with tardive dyskinesia in schizophrenia patients. 18th World Congress on Psychiatric Genetics, Athens, Greece, October 3-7, 2010
 155. Sockalingam S, Shammi C, Powell V, Remington G. Rates of hepatitis C in clozapine-treated patients with schizophrenia. 57th Academy of Psychosomatic Medicine, Marco Island, FL, November 10-13, 2010
 156. Agid O, Siu C, Potkin S, McDonald K, Remington G. Study quality and placebo response in randomized controlled trials in schizophrenia conducted 1996-2009. American Psychiatric Association 164th Annual Meeting, Honolulu, Hawaii, May 14-18, 2011
 157. Agid O, Siu C, Potkin S, McDonald K, Benattia I, Remington G. Study quality and placebo response in randomized controlled trials in schizophrenia conducted 1996-2009. NCDEU 51st Annual Meeting, Boca Raton, Florida, June 13-16, 2011
 158. Hahn M, Chintoh A, Lam L, Giacca A, Mann S, Fletcher P, Cohn T, Guenette MD, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. 37th Annual Harvey Stancer Research day, Toronto, Ontario, June 16, 2011
 159. Foussias G, Mann S, Zakzanis K, van Reekum R, Remington G. Motivational deficits as the key predictor of cross-sectional and longitudinal functioning in schizophrenia. 37th Annual Harvey Stancer Research day, Toronto, Ontario, June 16, 2011
 160. Ahuja T, Yu C, Verbrugghe S, Singh S, Remington G, Honer W. Is more better? Combination and high-dose antipsychotic therapy in patients with schizophrenia. Canadian Psychiatric Association 61st Annual Conference, Vancouver, British Columbia, October 13-15, 2011
 161. Agid O, Siu C, Ziursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1996 to 2010: a systematic review and meta-analysis. American College of Neuropsychopharmacology (ACNP) 50th Annual Meeting, Waikola, Hawaii,

- December 4-8, 2011
162. Voineskos A, Foussias G, Lerch J, Rajji T, Lobaugh N, Remington G, Kennedy J, Pollock B, Musant B. Subtyping schizophrenia using a multimodal neuroimaging approach. American College of Neuropsychopharmacology (ACNP) 50th Annual Meeting, Waikola, Hawaii, December 4-8, 2011
 163. Foussias G, Siddiqui I, Hasan N, McDonald K, Thavabalasingam S, Wong AHC, Zakzanis KK, Zawadski J, Fletcher P, Remington G. Assessing motivation in schizophrenia in a virtual environment. Canadian College of Neuropsychopharmacology, Vancouver, British Columbia, March 24-March 26, 2012
 164. Agid O, Siu CO, McDonald K, Tsoutsoullas C, Wass C, Foussias G, Remington G. Are patients with schizophrenia happy (Oral)? 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012
 165. De Luca V, Zai C, Remington G, Kennedy JL. Effect of geographical ancestry on tardive dyskinesia. 3rd Biennial Schizophrenia International Research Conference (Poster). Florence, Italy, April 14-18, 2012
 166. Fervaha G, Teo C, Mann S, Hahn M, Foussias G, Agid O, Remington G. Examining levels of antipsychotic adherence to better understand nonadherence in patients with schizophrenia (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012
 167. Agid O, Siu CO, Zipursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1966 to 2010: a systematic review and meta-analysis (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012
 168. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Receptor binding profiles of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012
 169. Hahn M, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Single dose administration of olanzapine: effects on glucose metabolism, endocrine and inflammatory markers in healthy volunteers (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012
 170. McCormick P, Fletcher P, Remington G. Effects of dopamine D₃ stimulation on reward learning: implications for adjunct treatment of antipsychotic-induced motivational impairment (Poster). 3rd Biennial Schizophrenia International Research Conference. Florence, Italy, April 14-18, 2012
 171. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Receptor binding profiles of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012
 172. Hahn M, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Single dose administration of olanzapine: effects on glucose metabolism in healthy volunteers (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012
 173. Menon M, Gerretsen P, Schmitz TW, Anderson AK, Mamo DS, Korostil M, Remington G, Kapur S, Graff-Guerrero A. Self-referential abnormalities may be trait vulnerabilities for the development of delusions (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012

174. Fervaha G, Menon M, Gerretsen P, Graff-Guerrero A, Schmitz T, Anderson A, Kapur S, Remington G. Whole-brain patterns of functional neural connectivity with the amygdala differentiates schizophrenia patients with and without delusions of reference (Poster). Society of Biological Psychiatry 67th Annual Meeting, Philadelphia, Pennsylvania, May 3-5, 2012 [Nominated for top poster].
175. Agid O, Siu C, Zipursky RB, Remington G. Time course of dropout rates in schizophrenia trials conducted from 1966 to 2010: a systematic review and meta-analysis. American Psychiatric Association 165th Annual Meeting, Philadelphia, Pennsylvania, May 5-9, 2012
176. Agid O, Siu CO, McDonald K, Tsoutsoullas C, Wass C, Foussias G, Remington G. Are patients with schizophrenia happy? American Psychiatric Association 165th Annual Meeting, Philadelphia, Pennsylvania, May 5-9, 2012
177. Caravaggio F, Suzuki T, Uchida H, Remington G, Borlido C, Pollock B, Mulsant B, De Luca V, Mamo D, Graff A. CNS half-life of ziprasidone in schizophrenia (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012
178. Fervaha G, Remington G. Whole-brain patterns of functional neural connectivity with the amygdala differentiates schizophrenia patients with and without delusions of reference (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012
179. Guenette MDG, Remington G. Receptor binding profile of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012
180. Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, Daskalakis ZJ. A meta-analysis of antipsychotic dopamine D2 receptor occupancy and clinical improvement in schizophrenia (Poster). IMS Scientific Day 2012, University of Toronto, May 15, 2012
181. Kennedy JL, Tiwari A, Brandl E, Chowdhury N, Zai C, Remington G. Genetic prediction of antipsychotic-induced weight gain and tardive dyskinesia: clinical application (Oral). International Congress of the Royal College of Psychiatrists. Liverpool, UK, July 10-13, 2012
182. McCormick P, Wilson V, Fletcher P, Remington G. Preliminary studies assessing the utility of the D₃ receptor for treatment of motivational impairment in schizophrenia (Oral). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012
183. Foussias G, Siddiqui I, Hasan N, McDonald K, Thavabalasingam S, Wong A, Zakzanis K, Zawadzki J, Fletcher P, Remington G. Assessing motivation in schizophrenia: development of a novel ecologically valid objective assessment methodology (Oral). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012
184. Hahn M, Wolever T, Arenovich T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Remington G. Single dose administration of olanzapine: effects on glucose metabolism in healthy volunteers (Oral). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012
185. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau, Pressner JC, Remington G, Houle S, Wislon AA. Increased stress-induced dopamine release in psychosis (Plenary). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012
186. Guenette M, Giacca A, Hahn M, Teo C, Lam L, Chitoh A, Fletcher P, Wolever T, Cohn T, Arenovich T, Remington G. Receptor binding profile of antipsychotic medications and glucose dysregulation: an acute animal model (Poster). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012 [Best Poster Award]
187. Jesus D, Digne M, Kennedy J, Remington G, Wong A, Daskalakis J. Transcranial

- magnetic stimulation to evaluate the role of clozapine potentiation of GABA in the treatment of schizophrenia (Poster). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012
188. McDonald K, Agid O, Tsoutsoulas C, Wass C, Foussias G, Remington G. Are patients with schizophrenia happy (Poster)? 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012
 189. Fervaha G, Menon M, Gerresten P, Graff-Guerrero A, Scmitz T, Anderson A, Kapur S, Remington G. Whole-brain patterns of functional neural connectivity with the amygdale differentiates schizophrenia patients with and without delusions of reference (Poster). 38th Annual Harvey Stancer Research Day, Toronto, Ontario, June 14, 2012
 190. Fervaha G, Remington G. Apathy and functioning in schizophrenia. 26th Annual Meeting of the Society for Research in Psychopathology. Ann Arbor, Michigan, October 4-7, 2012
 191. Agid O, Siu C, Zipursky RB, Remington G. Insight, treatment outcomes and recovery in first-episode schizophrenia. American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, Florida, Dec 2-6, 2012
 192. Foussias G, Siddiqui I, Hasan N, McDonald K, Thavabalasingam S, Zakzanis KK, Zawadski J, Fletcher P, Wong AHC, Remington G. Assessing motivation in schizophrenia in a virtual environment: development of a novel, ecologically valid assessment methodology. American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, Florida, Dec 2-6, 2012
 193. Duncan M, Cohn T, Remington G, Cairney J, Arbour-Nicitopoulos K, Faulkner G. Item refinement for a schizophrenia specific health action processes approach questionnaire. Eastern Canada Sport and Exercise Psychology Symposium, Brock University, Ontario, March 21, 2013.
 194. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Mueller DJ, Shaikh SA, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. The vesicular monoamine transporter gene SLC18A2 and tardive dyskinesia. Ontario Shores Centre for Mental Health Sciences 2nd Annual Research Day, Whitby, March 22, 2013
 195. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Mueller DJ, Shaikh SA, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. The vesicular monoamine transporter gene SLC18A2 and tardive dyskinesia. CINP: Pharmagenomics and Personalized Medicine in Psychiatry, Jerusalem, Israel, April 21-23, 2013
 196. Agid O, Siu CO, Harvey PD, Zipursky RB, Remington G. Insight, treatment outcomes and recovery in first-episode schizophrenia. 166th Annual American Psychiatric Association Meeting, San Francisco CA, USA, May 18-22, 2013
 197. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. First Annual NeuroMetabolic Meeting, University of Toronto, Toronto, Ontario, May 21-22, 2013
 198. Schulze L, Fletcher P, Nobrega JN, Remington G. Continuous vs. intermittent haloperidol dosing in rats: a behavioural examination of antipsychotic drug tolerance. Institute of Medical Science (IMS), University of Toronto, Annual Scientific Day, Toronto, May 28, 2013
 199. Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Motivation deficits in schizophrenia reflect impairments in the computation of effort during cost-benefit decision-making: a translational model. Institute of Medical Science (IMS), University of Toronto, Annual Scientific Day, Toronto, May 28, 2013

200. Agid O, Siu CO, Harvey PD, Zipursky RB, Remington G. Insight, treatment outcomes and recovery in first-episode schizophrenia. 53rd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Hollywood, Florida, May 28-31, 2013
201. Takeuchi H, Uchida H, Suzuki T, Bies RR, Watanabe K, Remington G, Mimura M. Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013
202. Schulze L, Fletcher P, Nobrega JN, Remington G. Continuous vs. intermittent haloperidol dosing in rats: a behavioural examination of antipsychotic drug tolerance. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013
203. Gerretsen P, Remington G, Borlido C, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Nakajima S, Caravaggio F, Deluca V, Ganguli R, Pollock BG, Graff-Guerrero A. Insight induction and anosognosia reversal in schizophrenia with caloric vestibular stimulation: a pilot proof of concept study. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013
204. Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Motivation deficits in schizophrenia reflect impairments in the computation of effort during cost-benefit decision-making: a translational model. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013
205. Graff-Guerrero A, Gerretsen P, Remington G, Borlido C, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Nakajima S, Caravaggio F, Mamo Dc, Rajji T, Mulsant BH, Deluca V, Ganguli R, Pollock BG. University of Toronto Insight Psychosis Scale (UTIP) self-report and rater versions. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013
206. Siddiqui I, Foussias G, Zakzanis K, Fletcher P, Remington G. Evaluation of novelty exploration and activity preference in schizophrenia using motion tracking. 36th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP), Toronto, May 29-June 1, 2013
207. Zai CC, Tiwari AK, Mazzoco M, de Luca V, Mueller DJ, Shaikh SA, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. The vesicular monoamine transporter gene SLC18A2 and tardive dyskinesia. The 12th Annual Pharmacogenetics in Psychiatry Meeting, Miami, Florida, May 31-June 1, 2013
208. Agid O, McDonald K, Siu C, Tsoutsoulas C, Wass C, Zipursky R, Foussias G, Remington G. Happiness in first-episode schizophrenia. Plenary address, 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
209. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
210. Schulze L, Fletcher P, Nobrega JN, Remington G. Continuous vs. intermittent haloperidol dosing in rats: a behavioural examination of antipsychotic drug tolerance. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
211. Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Motivation deficits in schizophrenia reflect impairments in the computation of effort during cost-benefit decision-making: a translational model. 39th Annual Harvey Stancer

- Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
212. Takeuchi H, Uchida H, Suzuki T, Bies RR, Watanabe K, Remington G, Mimura M. Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
 213. Voineskos A, Foussias G, Lerch J, Felsky D, Remington G, Rajji T, Lobaugh N, Pollock BG, Mulsant B. Evidence for the deficit subtype of schizophrenia. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
 214. Gerretsen P, Remington G, Borlido C, Hassan S, Ganguli R, Rajji TK, Mulsant BH, Deluca V, Pollock BG, Graff A. University of Toronto Insight into Psychosis Scale (UTIP) – self-report and rater version. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
 215. Siddiqui I, Foussias G, Zakzanis K, Fletcher P, Remington G. Evaluation of novelty exploration and activity preference in schizophrenia using motion tracking. 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
 216. Generoso S, McDonald K, Agid O, Fervaha O, Foussias G, Remington G. Caregivers of patients with schizophrenia: are they happy? 39th Annual Harvey Stancer Research Day, Department of Psychiatry, University of Toronto, June 13, 2013
 217. Agid O, Siu C, Harvey PD, Zipursky RB, Remington G. Insight, treatment and recovery in first-episode schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) 11th World Congress of Biological Psychiatry, Kyoto, Japan, June 23-27, 2013
 218. Siu CO, Agid O, Wayne M, Brambilla C, Remington G, Harvey PD. Insight into illness and subjective quality-of-life assessment in chronic schizophrenia. 26th Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 5-9, 2013
 219. Agid O, Siu C, Harvey PD, Zipursky RB, Remington G. Insight, treatment and recovery in first-episode schizophrenia. 26th Annual Meeting of the European College of Neuropsychopharmacology (ECNP), Barcelona, Spain, October 5-9, 2013
 220. McCormick PN, Fletcher PJ, Browne C, Wilson VS, Remington GJ. Inhibitory effects of pramipexole on conditioned reinforcement and locomotion are not mediated by dopamine D₃ receptors. 43rd Annual Society for Neuroscience Meeting, San Diego, CA, November 9-13, 2013
 221. Hahn M, Chintoh A, Remington G, Teo C, Mann S, Fletcher P, Cohn T, Giacca A. Weight gain independent, diabetogenic effects of olanzapine. 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 8-12, 2013
 222. Graff-Guerrero A, Fernando C, Shinichiro N, Gerretsen P, Mamo D, Remington G, Wilson A. Estimating endogenous dopamine levels at D₂ and D₃ receptors in humans using the agonist radiotracer [¹¹C]-[+]-PHNO. 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 8-12, 2013
 223. Duncan M, Arbour-Nicitopoulos K, Cairney J, Cohn T, Remington G, Faulkner G. Development and reliability testing of a health action process approach inventory for physical activity participation among individuals with schizophrenia. Society of Behavioral Medicine, Philadelphia, PA, April 23-26, 2014
 224. Gerretsen P, Menon M, Mamo DC, Remington G, Pollock BG, Graff-Guerrero A. Impaired illness awareness in schizophrenia spectrum disorders: resting state functional connectivity. Society of Biological Psychiatry 69th Annual Scientific Meeting, New York,

- NY, May 8-10, 2014
225. Siddiqui I, Foussias G, Fletcher PJ, Voineskos AN, Fervaha G, Zakzanis KK, Remington G. Objective evaluation of novelty exploration and activity preference in schizophrenia. Society of Biological Psychiatry 69th Annual Scientific Meeting, New York, NY, May 8-10, 2014
 226. Siu C, Agid O, Waye M, Brambilla C, Choi WK, Remington G, Harvey P. Insight into illness and uncooperativeness in chronic schizophrenia. American Psychiatric Association 167th Annual Meeting, May 3-7, 2014
 227. Siu C, Agid O, Waye M, Remington G, Harvey P. Insight into illness and uncooperativeness in chronic schizophrenia. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Hollywood, Fl, June 16-19, 2014
 228. Agid O, McDonald K, Fervaha G, Foussias G, Kantor N, Remington G. Illness progression after relapse in schizophrenia: antipsychotic re-challenge in previous responders. Harvey Stancer Research Day 40th Annual Meeting, Toronto, June 19, 2014
 229. Ganguli R, Hassan S, Bhamani MA, Jemkins T, Remington G, Cohn T, Agid O. Prevention of weight gain in early psychosis: a randomized controlled clinical trial of a stepped behavioural intervention. Canadian Psychiatric Association (CPA) 64th Annual Meeting, Toronto, Ontario, September 11-13, 2014
 230. Kalahani-Bargis K, Foussias G, Remington G, Zakzanis K, Jeffay E. Longitudinal analysis of verbal fluency in chronic schizophrenia. National Academy of Neuropsychology (NAN) 34th Annual Meeting, Fajardo, Puerto Rico, November 12-15, 2014
 231. Agid O, Siu C, Zipursky R, Fervaha G, Foussias G, Remington G. Antipsychotic re-challenge in previous responders. 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Phoenix, Arizona, December 7-11, 2014
 232. Grimes KM, Zanjani A, Foussias G, Remington G, Zakzanis KK. Memory and the mediating role of task difficulty in patients with schizophrenia. Southern Ontario Neuroscience Association (SONA) Annual Meeting, McMaster University, Hamilton, Ontario, May 1, 2015
 233. Takeuchi H, Lee J, Foussias G, Agid O, Remington G. Switching to clozapine using immediate vs. gradual antipsychotic discontinuation: a pilot, Double-blind, randomized, controlled trial. 2014 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), Miami, Florida, June 24, 2015

D.2 Invited Lectures

- The acutely psychotic patient: emergency treatment and neuroleptization. Training lectures for McNeil Pharmaceuticals (Canada) Ltd, October 1985, February 1986, September 1986
- Alopecia areata and its psychological impact. Canadian Alopecia Areata Association, Toronto, Ontario, October 1987
- Systems of pharmacotherapeutics intervention in schizophrenia. Conference on Systems of Care for the Chronic Schizophrenic Patient, Toronto, Ontario, March 1988
- Psychotropic drug use in the mentally retarded. Metropolitan Toronto Association for the Mentally Retarded, Toronto, Ontario, March 1988
- The borderline syndrome: evolution and etiology. Conference on the Characterologically Disturbed Patient: The Challenge of the 90's, Toronto, Ontario, November 1988

The residual phase of schizophrenia. Conference on Phases of Schizophrenia, Ottawa, Ontario, February 1989

Pharmacotherapy of schizophrenia: the last five years.

- (i) Department of Psychiatry, University of Western Ontario, London, Ontario, May 1989
- (ii) Grand Rounds, Department of Psychiatry, Scarborough-Grace Hospital, Toronto, Ontario, September 1989
- (iii) Memorial University, Department of Psychiatry, Waterford Hospital, St. John's, Newfoundland, October 1989
- (iv) Medical Staff, Centracare Hospital. Saint John, New Brunswick, October 1989
- (v) Grand Rounds, Department of Psychiatry, Camp Hill Hospital, Halifax, Nova Scotia, October 1989

Pharmacotherapy of schizophrenia. Grand Rounds, Department of Psychiatry, Toronto East General Hospital, Toronto, Ontario, January 1990

The interface of medication and psychological treatment. Symposium on Medications and Psychotherapy, Ontario Psychiatric Association, Toronto, Ontario, February 1990

Update on neuroleptics.

- (i) Department of Psychiatry, Douglas Hospital, Montreal, Quebec, March 1990
- (ii) Grand Rounds, Department of Psychiatry, Montreal General Hospital, Montreal, Quebec, March 1990

The atypical remitting psychoses, Department of Psychiatry, Montreal General Hospital, Montreal, Quebec, March 1990

The evolution of pharmacotherapy. Conference on Clinical Evolution in the Psychiatric Hospital. Niagara-on-the Lake, Ontario, April 1990

The interface of psychology and psychopharmacology. Department of Psychiatry, York University, Toronto, Ontario, May 1990, October 1990, October 1991, October 1992

Current perspectives in schizophrenia.

- (i) Grand Rounds, University of Alberta, Department of Psychiatry, Alberta Hospital, Edmonton, Alberta, May 1990
- (ii) Grand Rounds, University of British Columbia, Department of Psychiatry, Vancouver General Hospital, Vancouver, British Columbia, May 1990
- (iii) Grand Rounds, University of British Columbia, Department of Psychiatry, Riverview Hospital, Port Coquitlam, British Columbia, May 1990

Managing the long-term side effects of neuroleptics. Conference on Integrating Health Care: A Perspective for the 90's, Toronto, Ontario, October 1990

Mental Illness – myths and realities: two case histories. Ninth Annual Pharmacy Technicians Conference, Toronto, Ontario, November 1990

Combining medications and psychotherapy. Workshop presented by the Clinical Section of the Ontario Psychiatric Association, Toronto, Ontario, November 1990

Rational use of psychotropic medications. Pharmaceutical Manufacturers Association of Canada Education Day, Toronto, Ontario, April 1991

Psychotropic medications in developmentally handicapped children. Beverley School Professional Development Day, May 1991

The clinical value of plasma neuroleptic levels. Symposium on Drug Therapy in Schizophrenia – Variability of Outcome and Prediction of Response. Canadian College of Neuropsychopharmacology XIV Annual Meeting, June 1991

- Clinical measurements of akathisia. Symposium on Assessment of Drug Induced EPS and Dystonic Movements. Canadian College of Neuropsychopharmacology XIV Annual Meeting, June 1991
- Depot Neuroleptics. Roundtable Discussion on Issues in the Management of Chronic Schizophrenia. Cambridge, Ontario, September 20, 1991
- Schizophrenia and new developments in antipsychotic drugs. Ontario Friends of Schizophrenia, Thunder Bay, Ontario, October 28, 1991
- Recent developments in antipsychotic medications. Lakehead Psychiatric Hospital, Thunder Bay, Ontario, October 29, 1991
- Neuroleptic-induced movement disorders. Victoria Hospital Department of Psychiatry, University of Western Ontario, London, Ontario, November 4, 1991
- Pathophysiologic basis of schizophrenia: typical and atypical neuroleptics. Merrell Dow Education Day, November 5, 1991
- Neuroleptics: An update. St. Michael's Hospital, Toronto, Ontario, April 2, 1992
- Neuroleptics and side effects. Community Rehabilitation Services Program, Community Resource Consultants of Toronto, Toronto, Ontario, May 19, 1992
- Current perspectives in the treatment of schizophrenia. Department of Psychiatry, University Hospital, University of British Columbia, Vancouver, British Columbia, July 23, 1992
- Novel antipsychotics in the treatment of schizophrenia: risperidone. Pharmacy Specialty Group in Psychiatry, Canadian Society of Hospital Pharmacists, Toronto Chapter, Toronto, Ontario, October 14, 1992
- A systematic approach to treatment-resistant schizophrenia. Grand Rounds, Toronto General Hospital, Toronto, Ontario, October 30, 1992
- Insight, negative symptoms and neurocognitive functioning. University of Manitoba, Winnipeg, Manitoba, November 2, 1992
- New and atypical neuroleptics in schizophrenia: risperidone. Selkirk Mental Health Centre, Selkirk, Manitoba, November 2, 1992
- Atypical psychoses. Grand Rounds, University of Manitoba, Winnipeg, Manitoba, November 3, 1992
- Risperidone in chronic schizophrenia: a US-Canadian multicentre trial. St. Thomas Psychiatric Hospital, St. Thomas, Ontario, November 4, 1992
- A review of long-acting neuroleptics. Grand Rounds, London Psychiatric Hospital, London, Ontario, November 19, 1992
- Strategies in the management of treatment-resistant schizophrenia. Medical Rounds, Penetanguishene Mental Health Centre, Penetanguishene, Ontario, November 20, 1992
- Update on novel and atypical antipsychotics. Community Occupational Therapists and Associates, Toronto, Ontario, January 14, 1993
- Pharmacotherapy of schizophrenia: an update. Ontario Psychiatric Association 73rd Annual Meeting, Toronto, Ontario, January 29, 1993
- Novel antipsychotics: theoretical and clinical implications.
- (i) Grand Rounds, St. Mary's Hospital, Montreal, Quebec, February 18, 1993
 - (ii) Grand Rounds, Douglas Hospital, Montreal, Quebec, March 11, 1993
 - (iii) Grand Rounds, Montreal General Hospital, Montreal, Quebec, March 12, 1993
 - (iv) Grand Rounds, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, March 26, 1993
 - (v) Department of Psychiatry, Memorial University, St. John's, Newfoundland, April 6, 1993
 - (vi) Grand Rounds, Waterford Hospital, St. John's, Newfoundland, April 7, 1993

- Understanding and treating schizophrenia in light of new advances. Brockville Psychiatric Hospital, Brockville, Ontario, March 24, 1993
- Awakenings in patients with schizophrenia: the clinician's perspective. Psychomotor and Cognitive Impairment in Schizophrenia: Assessment and Clinical Implications, Toronto, Ontario, April 3, 1993
- Neuroleptic-induced movement disorders. Memorial University, St. John's, Newfoundland, April 7, 1993
- Intolerance to antipsychotic medications in schizophrenic patients: what next? London Psychiatric Hospital. London, Ontario, April 15, 1993
- Neuroleptic-induced movement disorders, York Community Services, Toronto, Ontario, April 16, 1993
- Novel and atypical antipsychotics. Grand Rounds, Peel Memorial Hospital, Brampton, Ontario, April 23, 1993
- Understanding and treating schizophrenia in light of new advances. The Windsor Academy of Psychiatry, Windsor, Ontario, April 27, 1993
- Schizophrenia – new and alternative drug treatment. Branson Hospital, Toronto, Ontario, April 28, 1993
- New and alternative treatments in the pharmacotherapy of schizophrenia. Lakehead Psychiatric Hospital, Thunder Bay, Ontario, April 30, 1993
- Rational management of movement disorders caused by neuroleptics. Saskatoon City Hospital, Department of Psychiatry, Saskatoon, Saskatchewan, May 13, 1993
- Current perspectives in schizophrenia. Royal University Hospital, Department of Psychiatry, Saskatoon, Saskatchewan, May 14, 1993
- Understanding and treating schizophrenia in light of new advances. Royal University Hospital, Department of Psychiatry, Saskatoon, Saskatchewan, May 14, 1993
- Novel and atypical neuroleptics in the treatment of schizophrenia. Greater Vancouver Mental Health Services Society, Vancouver, British Columbia, June 1, 1993
- Treatment resistant schizophrenia: a systematic approach. Psychiatry Grand Rounds, Vancouver General Hospital, Vancouver, British Columbia, June 1, 1993
- Recent advances in the diagnosis and management of schizophrenia. Psychiatry Grand Rounds, Mississauga Hospital, Mississauga, Ontario, June 2, 1993
- Depot neuroleptics in the treatment of schizophrenia. Department of Psychiatry, Toronto General Hospital, Toronto, Ontario, June 18, 1993
- Management of neuroleptic-induced movement disorders. Grand Rounds, Whitby Psychiatric Hospital, Whitby, Ontario, July 23, 1993
- Schizophrenia spectrum disorders and the use of neuroleptics. Department of Psychiatry, Mount Sinai Hospital, Toronto, Ontario, July 29, 1993
- Clinical perspectives of risperidone. Department of Psychiatry, Centenary Health Centre, Scarborough, Ontario, September 21, 1993
- New drugs in psychiatry: an update. Ontario Friends of Schizophrenia, Toronto, Ontario, September 22, 1993
- Neuroleptic side effects and newer treatments. Schizophrenia '93: Promising Developments, Saskatoon, Saskatchewan, October 7, 1993
- Rational management of movement disorders in schizophrenia. Workshop for Schizophrenia '93: Promising Developments, Saskatoon, Saskatchewan, October 7, 1993
- Movement disorders. New Perspectives on Schizophrenia: Clinical Implications, Edmonton, Alberta, October 8, 1993

- Movement disorders in schizophrenia: cause and treatment. Workshop for New Perspectives on Schizophrenia: Clinical Implications, Edmonton, Alberta, October 8, 1993
- The pharmacology of new neuroleptics. Department of Psychiatry, Toronto East General Hospital, Toronto, Ontario, October 15, 1993
- Psychopharmacology of schizophrenia: an update. Department of Psychiatry, Oshawa General Hospital, Oshawa, Ontario, October 20, 1993
- Neuroleptic side effects. Lederle Preceptorship Program, Toronto, Ontario, November 4, 1993
- Novel and atypical antipsychotics. Department of Psychiatry, Scarborough Grace Hospital, Scarborough, Ontario, November 5, 1993
- Neuroleptic-induced movement disorders. Department of Psychiatry, Scarborough General Hospital, Scarborough, Ontario, January 20, 1994
- Chair, Symposium: What's New in Schizophrenia: A Clinical Update. Ontario Psychiatric Association 74th Annual Meeting, Toronto, Ontario, January 1994
- Pharmacotherapy of schizophrenia: new developments. Symposium: What's New in Schizophrenia: A Clinical Update. Ontario Psychiatric Association 74th Annual Meeting, Toronto, Ontario, January 1994
- Advances in medications for schizophrenia. Public forum "Ensuring Access to Treatment Advances in Schizophrenia: The Psychiatrist's Role". Ontario Psychiatric Association 74th Annual Meeting, Toronto, Ontario, January 26, 1994
- The role of dopamine and serotonin in neuroleptic-induced movement disorders.
- (i) Department of Psychiatry, St. Mary's Hospital, Montreal, Quebec, February 17, 1994
 - (ii) Department of Psychiatry, Allan Memorial Hospital, Montreal, Quebec, February 17, 1994
 - (iii) Department of Psychiatry, Jewish General Hospital, Montreal, Quebec, February 17, 1994
 - (iv) Department of Psychiatry, Montreal General Hospital, Montreal, Quebec, February 18, 1994
- Management of neuroleptic-induced movement disorders.
- (i) Department of Psychiatry, Laurentian Hospital, Sudbury, Ontario, February 23, 1994
 - (ii) Grand Rounds, North Bay Psychiatric Hospital, North Bay, Ontario, February 24, 1994
- Schizophrenia and new antipsychotic drugs. Ontario Friends of Schizophrenics, St. Catherines Chapter, St. Catherine's, Ontario, March 2, 1994
- Theoretical implications of balanced 5-HT/DA in the positive and negative symptoms of schizophrenia. Hosp. Lafontaine, Montreal, Quebec, March 15, 1994
- New antipsychotic medications. Drugs and Therapeutics Update, Toronto East General Hospital, Toronto, Ontario, April 20, 1994
- Serotonergic and dopaminergic antagonism in the role of novel antipsychotics. Grand Rounds, Laurentian Psychiatric Hospital, Thunder Bay, Ontario, May 2, 1994
- Current treatment strategies in schizophrenia: an update for general practitioners. Thunder Bay, Ontario, May 2, 1994
- Extrapyramidal Symptom Rating Scale (ESRS). Grand Rounds, Whitby Psychiatric Hospital, Whitby, Ontario, May 6, 1994
- Extrapyramidal Symptom Rating Scale (ESRS) workshop for clinicians. Whitby Psychiatric Hospital, Whitby, Ontario, May 6, 1994

- Novel antipsychotics in the treatment of schizophrenia. Mississauga Hospital, Mississauga, Ontario, May 18, 1994
- Neuroleptic-induced movement disorders. Brockville Psychiatric Hospital, Brockville, Ontario, May 19, 1994
- Workshop for clinicians using the Extrapyrimal Symptom Rating Scale (ESRS). Brockville Psychiatric Hospital, Brockville, Ontario, May 19, 1994
- New treatments for schizophrenia. Ontario Government Pharmaceutical and Medical Supply Service Pharmacists' Meeting 1994, Toronto, Ontario, June 1, 1994
- Chair, Symposium: Reappraisal of the Role of Depot Neuroleptics. Kitchener, Ontario, June 3, 1994
- The role of depot neuroleptics in the management of schizophrenia. Symposium: Reappraisal of the Role of Depot Neuroleptics. Kitchener, Ontario, June 3, 1994
- The latest in antipsychotics. Psychiatry Institute for Medical Students, Toronto, Ontario, June 6, 1994
- Neuroleptic-induced movement disorders. Department of Psychiatry, St. Joseph's Hospital, Toronto, Ontario, June 7, 1994
- The clinical use of novel neuroleptics. Kitchener, Ontario, June 22, 1994
- The role of novel neuroleptics in refractory schizophrenia. Etobicoke, Ontario, July 4, 1994
- New research in the development of neuroleptics. Schizophrenia Society of Canada 1994 Annual Conference, Ottawa, Ontario, August 12, 1994
- Chair, Symposium: Phases of Psychosis: Pharmacological Management. Schizophrenia 1994: Exploring the Spectrum of Psychosis, Vancouver, British Columbia, August 22, 1994
- Movement disorders: management and prevention. Grand Rounds, Markham Stouffville Hospital, Markham, Ontario, September 16, 1994
- Co-Chair, Ramzy Yassa Memorial Symposium: Tardive Dyskinesia 1994: Update. Canadian Psychiatric Association 44th Annual Meeting, Ottawa, Ontario, September 22, 1994
- First episode psychosis: assessment and treatment. Grand Rounds, Department of Psychiatry, Sunnybrook Hospital, Toronto, Ontario, September 30, 1994
- Pharmacotherapy of schizophrenia: an update. Department of Psychiatry, The Grey Bruce Regional Health Centre, Owen Sound, Ontario, October 6, 1994
- Clinical use of novel antipsychotic agents: risperidone. Department of Psychiatry, Centenary Hospital, Scarborough, Ontario, October 12, 1994
- Risperidone: a clinical update. Whitby Psychiatric Hospital, Whitby, Ontario, October 20, 1994
- Enhancing response to psychotropic medication: side effects. 2nd Annual Psychopharmacology Clinical Day, University of Toronto, Department of Psychiatry, Toronto, Ontario, October 20, 1994
- Chair, Schizophrenia Medical Seminar. Parry Sound, Ontario, October 21-23, 1994
- Pharmacotherapy of schizophrenia – acute treatment. Schizophrenia Medical Seminar, Parry Sound, Ontario, October 21-23, 1994
- A look at acute management. Workshop, Schizophrenia Medical Seminar, Parry Sound, Ontario, October 21-23, 1994
- Achieving serotonergic and dopaminergic blockade: implications for schizophrenia and depression. Mood Disorders: Current Opinion, Dalhousie University, Halifax, Nova Scotia, November 5, 1994
- An update on antipsychotics. University of Toronto Health Service, Toronto, Ontario, November 7, 1994
- The middle years: current medication choices. Schizophrenia: Management Strategies Across the Lifespan. Queen Street Mental Health Centre, Toronto, Ontario, December 2, 1994

- Neuroleptics: clinical guidelines and potential drug interactions (workshop with K. Butler).
Schizophrenia: Management Strategies Across the Lifespan. Queen Street Mental Health Centre, Toronto, Ontario, December 2, 1994
- Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Wellesley Hospital, Toronto, Ontario, January 13, 1995
- Development of new antipsychotics.
- (i) Kwai Chung Hospital, Hong Kong, January 23, 1995
 - (ii) Castle Peak Hospital, Hong Kong, January 25, 1995
- The role of serotonin-dopamine antagonism in the development of novel antipsychotics. The Hong Kong College of Psychiatrists, Hong Kong, January 24, 1995
- The dichotomy of schizophrenia – positive and negative symptoms: trends in management. Philippine Psychiatric Association 20th Annual Convention, Cebu, The Philippines, January 27, 1995
- Approaches to evaluating and managing treatment resistant patients. Treatment Challenges in Schizophrenia. University of Pittsburgh, Pittsburgh, Pennsylvania, February 4, 1995
- Development of new antipsychotics. Workshop with Dr. S. Kapur, Treatment Challenges in Schizophrenia. University of Pittsburgh, Pittsburgh, Pennsylvania, February 4, 1995
- Schizophrenia and depression. Humber Memorial Hospital, Toronto, Ontario, March 7, 1995
- The role of dopamine and serotonin in neuroleptic-induced EPS. Grand Rounds, Department of Psychiatry, Calgary General Hospital, Calgary, Alberta, March 17, 1995
- First episode psychosis and the evolution of schizophrenia. Grand Rounds, Department of Psychiatry, University Hospital, University of Edmonton, Edmonton, Alberta, March 20, 1995
- Neuroleptic-induced EPS: diagnosis and treatment. Community Living Program, Edmonton, Alberta, March 20, 1995
- The role of dopamine and serotonin in neuroleptic-induced EPS. Grand Rounds, Department of Psychiatry, Foothills General Hospital, Calgary, Alberta, March 21, 1995
- First episode psychosis and the evolution of schizophrenia. Grand Rounds, Department of Psychiatry, Foothills General Hospital, Calgary, Alberta, March 21, 1995
- Schizophrenia and depression. Medical Staff, Mental Health Centre, Penetanguishene, Ontario, March 24, 1995
- Neuroleptic-induced EPS: diagnosis and management. Schizophrenia Program, Department of Psychiatry, University of Winnipeg, Winnipeg, Manitoba, April 3, 1995
- First break psychosis. Department of Psychiatry, University of Winnipeg, Winnipeg, Manitoba, April 3, 1995
- Rational management of neuroleptic-induced movement disorders. Grand Rounds, Department of Psychiatry, University of Winnipeg, Winnipeg, Manitoba, April 4, 1995
- First episode psychosis and the evolution of schizophrenia. Medical Staff, Brandon Mental Health Centre, Brandon, Manitoba, April 4, 1995
- Assessment of EPS and the use of the ESRS. Brandon Mental Health Centre, Brandon, Manitoba, April 4, 1995
- Schizophrenia and depression. Program for Psychiatrists and Family Doctors. Toronto, Ontario, April 13, 1995
- Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Department of Psychiatry, Women's College Hospital, Toronto, Ontario, May 26, 1995
- First episode psychosis. Grand Rounds, Lakehead Psychiatric Hospital, Thunder Bay, Ontario, June 1, 1995
- Neuroleptic-induced EPS: diagnosis and management. Workshop, Lakehead Psychiatric

- Hospital, Thunder Bay, Ontario, June 1, 1995
- Atypical neuroleptics. Grand Rounds, Sunnybrook Health Science Centre, Toronto, Ontario, June 2, 1995
- ESRS: Extrapyramidal Symptom Rating Scale. Workshop, Sunnybrook Health Science Centre, Toronto, Ontario, June 2, 1995
- Movement disorders in schizophrenia – managing neuroleptic side effects, Atlantic Provinces Psychiatric Association Annual Meeting, Moncton, New Brunswick, June 10, 1995
- Assessment and management of neuroleptic-induced EPS. Workshop, Atlantic Provinces Psychiatric Association Annual Meeting, Moncton, New Brunswick, June 10, 1995
- Schizophrenia and depression. Psychiatry Rounds, York-Finch Hospital, Toronto, Ontario, June 20, 1995
- An update on the neurobiology of psychosis. Waterford Update, Schizophrenia '95: Improving Quality of Life, St. John's Newfoundland, June 23, 1995
- Managing movement disorders in schizophrenia. Workshop, Waterford Update, Schizophrenia '95: Improving Quality of Life, St. John's Newfoundland, June 23, 1995
- First episode schizophrenia – definition and prognosis. Current Issues in First Episode Schizophrenia, London, England, July 4, 1995
- Issues in the choice of neuroleptics in first episode schizophrenia. Current Issues in First Episode Schizophrenia, London, England, July 4, 1995
- Practical aspects of dosage regimens. Current Issues in First Episode Schizophrenia, London, England, July 4, 1995
- Neuroleptic, new compounds, and changing concepts. Burlington, Ontario, July 21, 1995
- Newer antipsychotics in the treatment of schizophrenia. Advances in Schizophrenia: a Roundtable Meeting, Seoul, South Korea, September 1, 1995
- Schizophrenia: new theories and novel antipsychotics. Joint Annual Meeting of the Korean Society of Biological Psychiatry & the Korean Society of Psychopharmacology, Seoul, South Korea, September 2, 1995
- Advances in the pharmacotherapy of schizophrenia. Seoul National University, Seoul, South Korea, September 3, 1995
- Schizophrenia: changing concepts and the development of novel antipsychotics.
- (i) Fukushima Medical College, Fukushima, Japan, September 5, 1995
 - (ii) School of Medicine, Kanazawa University, Kanazawa, Japan, September 7, 1995
 - (iii) School of Medicine, Keio University, Tokyo, Japan, September 8, 1995
 - (iv) Department of Psychiatry, University of Philippines, Manila, Philippines, September 13, 1995
- First episode schizophrenia: issues in the choice of antipsychotics. Department of Neurology & Psychiatry, University of Santo Tomas, Manila, Philippines, September 14, 1995
- The development of novel antipsychotics. Indonesia Psychiatric Society, Jakarta, Indonesia, September 16, 1995
- Clinical implications of novel antipsychotics. Dharmawangsa Study Group on Schizophrenia: a Roundtable Meeting, Jakarta, Indonesia, September 17, 1995
- Novel antipsychotics: theory and clinical implications. Semarang State Mental Hospital, Semarang, Indonesia, September 18, 1995
- The dichotomy of schizophrenia – positive and negative symptoms: trends in management. The Psychiatric Association of Thailand, Bangkok, Thailand, September 21, 1995
- Schizophrenia and depression. Grand Rounds, Queen Street Mental Health Centre, Toronto, Ontario, September 29, 1995
- Neuroleptic-induced EPS: recognition and management. Hamilton Psychiatric Hospital,

- Hamilton, Ontario, October 11, 1995
- Assessment of neuroleptic-induced EPS. Workshop, Hamilton Psychiatric Hospital, Hamilton, Ontario, October 11, 1995
- Neuroleptics: the development of novel compounds. Kitchener, Ontario, October 11, 1995
- The evaluation and management of neuroleptic-induced movement disorders in first episode psychosis. Workshop, First Episode Psychosis II: Onset, Diagnosis, Management. Clarke Institute of Psychiatry, Toronto, Ontario, October 13, 1995
- Clinical issues in the management of psychosis. Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, October 16, 1995
- Neuroleptics: novel compounds and their clinical application. Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, October 17, 1995
- Clinical issues in the management of psychosis. Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba, October 17, 1995
- Neuroleptics: new compounds and changing concepts. An update for general psychiatrists. Etobicoke, Ontario, October 19, 1995
- What's new in schizophrenia: treatment and management. Psychiatry Rounds, Department of Psychiatry, University of Alberta, Edmonton, Alberta, October 23, 1995
- The role of zuclopenthixol in the management of psychosis. Department of Psychiatry, University of Alberta, Edmonton, Alberta, October 23, 1995
- What's new in schizophrenia: treatment and management. Psychiatry Rounds, Department of Psychiatry, University of Calgary, Calgary, Alberta, October 24, 1995
- The management of acute psychosis. Emergency Psychiatry Workshop, Departments of Psychiatry and Emergency Medicine, University of Calgary, Calgary, Alberta, October 24, 1995
- Recent developments in schizophrenia. Conference on Schizophrenia and the Family, Canadian Mental Health Foundation, New Brunswick Division.
- (i) Moncton, New Brunswick, October 25, 1995
 - (ii) St. John, New Brunswick, October 26, 1995
 - (iii) Fredericton, New Brunswick, October 27, 1995
- Schizophrenia: changing concepts and the development of novel antipsychotics.
- (i) Department of Psychiatry, St. John Regional Hospital, St. John, New Brunswick, October 26, 1995
 - (ii) Department of Psychiatry, Dr. Everett Chalmer's Hospital, Fredericton, New Brunswick, October 27, 1995
- Managing schizophrenia: the physician's role. A Clinical Day on the Management of the Seriously Mental Ill in the Community. North Bay General Hospital, North Bay, Ontario, November 8, 1995
- New developments in the treatment of schizophrenia. North Bay Medical Society, North Bay, Ontario, November 8, 1995
- Phases of psychosis: pharmacologic considerations. Whitby, Ontario, November 14, 1995
- Identification and management of neuroleptic-induced EPS. Department of Psychiatry, Toronto East General Hospital, Toronto, Ontario, November 22, 1995
- What's new in the treatment of schizophrenia. Conference on Schizophrenia: Enhancing Partnership in Treatment Compliance, Whitby Mental Health Centre, Whitby, Ontario, November 24, 1995
- Dopamine and serotonin receptor mechanisms in the action of atypical antipsychotics. Conference on Schizophrenia 95, Montreal, Quebec, December 1, 1995
- The role of zuclopenthixol acetate in acute psychosis. Clarke Institute of Psychiatry, Toronto,

- Ontario, December 2, 1995
- Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Department of Psychiatry, University of Ottawa, Ottawa, Ontario, December 20, 1995
- Pharmacotherapy of schizophrenia: from first episode to chronic treatment. Grand Rounds, Department of Psychiatry, Queen's University, Kingston, Ontario, January 19, 1996
- Schizophrenia: current treatment and research. Comcare Canada, Toronto, Ontario, February 22, 1996
- Evolution of antipsychotics: changing concepts and the development of new compounds. Veterans' General Hospital, Tapei, Taiwan, March 26, 1996
- Schizophrenia: changing concepts and the development of novel antipsychotics.
- (i) Taiwan Psychiatric Society, Tapei, Taiwan, March 26, 1996
 - (ii) Kaohsiung Psychiatric Society, Kaohsiung, Taiwan, March 27, 1996
 - (iii) Veterans' General Hospital, Taichung, Taiwan, March 28, 1996
- Pharmacologic management of first episode schizophrenia. Indonesian Psychiatric Society, Jakarta, Indonesia, March 30, 1996
- Practical issues in the pharmacotherapy of schizophrenia. Darmawangsa Hospital, Jakarta, Indonesia, March 30, 1996
- Pharmacotherapy of schizophrenia: from theory to clinical practice.
- (i) Surabaya Psychiatric Society, Surabaya, Indonesia, March 30, 1996
 - (ii) Yogyakarta Psychiatric Society, Jakarta, Indonesia, April 1, 1996
 - (iii) Medan Psychiatric Society, Medan, Indonesia, April 2, 1996
- Schizophrenia: changing concepts and the development of novel antipsychotics. Department of Psychiatry. Dalhousie University, Halifax, Nova Scotia, April 10, 1996
- Standard and novel neuroleptics: clinical guidelines.
- (i) St. Mary's Hospital, Montreal, Quebec, April 11, 1996
 - (ii) The Douglas Hospital, Montreal, Quebec, April 11, 1996
 - (iii) Jewish General Hospital, Montreal, Quebec, April 11, 1996
- Standard and novel neuroleptics: theory and clinical guidelines. Managing Severe Mental Illness – A Day in Schizophrenia, Sudbury, Ontario, May 11, 1996
- Neuroleptic-induced EPS: diagnosis and management. Workshop presented at Managing Severe Mental Illness – A Day in Schizophrenia, Sudbury, Ontario, May 11, 1996
- Negative symptoms in schizophrenia. Ontario Friends of Schizophrenics – East York Chapter, Toronto East General Hospital, Toronto, Ontario, May 14, 1996
- Managing the aggressive patient. Kitchener, Ontario, May 16, 1996
- Advances in neuroleptic therapy. Department of Psychiatry, The Toronto Hospital, Toronto, Ontario, May 17, 1996
- Past and present neuroleptics. The Medications Used to Treat Schizophrenia: Past, Present and Future. Credit Valley Hospital, Toronto, Ontario, May 21, 1996
- Managing the agitated and violent schizophrenic patient. Séminaire Médical en Psychiatrie, L'Association des Médecins Psychiatres du Québec, Stowe, Vermont, May 24-26, 1996
- The use of zuclopenthixol acetate in the management of acute psychosis. Mississauga, Ontario, May 28, 1996
- Neuroleptics: new compounds and changing concepts. Calgary 1996 Schizophrenia Conference, Calgary, Alberta, June 4, 1996
- Neuroleptic-induced movement disorders. Workshop presented at Calgary 1996 Schizophrenia Conference, Calgary, Alberta, June 4, 1996
- Neuroleptic-induced movement disorders; diagnosis and management. Riverview Hospital 2nd Annual Schizophrenia Conference, Riverview Hospital, British Columbia, June 5, 1996

- The management of agitated and violent psychotic patients. Oakville, Ontario, June 20, 1996
- Treatment-resistant schizophrenia: pharmacotherapy. West End Mental Health Team, Greater Vancouver Mental Health Service Society, Vancouver, British Columbia, October 8, 1996
- Treatment-resistant schizophrenia. Workshop, management of treatment-resistant mental illness. The Fourth Annual Clinical Psychopharmacology Day, University of Toronto, Toronto, Ontario, October 17, 1996
- Newer neuroleptics in the treatment of schizophrenia. Psychiatry Rounds, St. Joseph's Hospital, Toronto, Ontario, October 22, 1996
- Pharmacotherapy of schizophrenia: practical guidelines. Annual Clinic Day: Family Practice Update, North York Branson Hospital, Toronto, Ontario, October 23, 1996
- Neuroleptics 2000: practical guidelines after fifty years experience. Mental Health Centre, Penetanguishene, Ontario, November 20, 1996
- Neuroleptic-induced movement disorders: assessment and treatment. Medical Rounds, Mental Health Centre, Penetanguishene, Ontario, November 20, 1996
- Pharmacotherapy of first episode psychosis. The Hospital for Sick Children 2nd Annual Psychopharmacology Day, Toronto, Ontario, November 21, 1996
- Novel neuroleptics, mechanisms of action, and clinical implications. Biannual Meeting of the Ontario Provincial Hospitals' Directors of Pharmacy, Queen Street Mental Health Centre, Toronto, Ontario, November 21, 1996
- Novel neuroleptics, mechanisms of action, and clinical implications. Psychiatry Rounds, Women's College Hospital, Toronto, Ontario, November 29, 1996
- Novel neuroleptics, mechanisms of action, and clinical implication. Grand Rounds, Department of Psychiatry, Wellesley-St. Michael's Hospital, Toronto, Ontario, December 6, 1996
- New developments in the psychopharmacological treatment of schizophrenia. 'First Episode Psychosis III: Onset, Diagnosis, Management' Conference, Clarke Institute of Psychiatry, Toronto, Ontario, January 22, 1997
- Practical guidelines in the use of neuroleptics. . 'First Episode Psychosis III: Onset, Diagnosis, Management' Conference, Clarke Institute of Psychiatry, Toronto, Ontario, January 22, 1997
- Assessment and management of neuroleptic-induced EPS.
- (i) Psychiatry Grand Rounds, St. Mary's Hospital, Montreal, Quebec, January 23, 1997
 - (ii) Grand Rounds, Douglas Hospital, Montreal, Quebec, January 23, 1997
 - (iii) Psychiatry Grand Rounds, Montreal General Hospital. Montreal, Quebec, January 25, 1997
- Assessment, diagnosis and early intervention in schizophrenia. Vancouver, British Columbia, March 5, 1997
- Psychotic illness and the therapeutic alliance. Greater Vancouver Mental Health Service Society Staff Day, Vancouver, British Columbia, March 6, 1997
- Assessment and management of neuroleptic-induced EPS. Psychiatry Grand Rounds, Royal University Hospital, Saskatoon, Saskatchewan, March 7, 1997
- Standard and novel antipsychotics: theory and clinical guidelines, Remington G, Teehan M. Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, March 7, 1997
- Schizophrenia: early detection and diagnosis. 'Waterford Update – Schizophrenia 97' Conference. Waterford Hospital, St. John's. Newfoundland, March 10, 1997
- Assessment and management of neuroleptic-induced EPS. 'Waterford Update – Schizophrenia

- 97' Conference. Waterford Hospital, St. John's. Newfoundland, March 10, 1997
- Pharmacotherapy and early intervention: integrating theory and clinical practice. 'Waterford Update – Schizophrenia 97' Conference. Waterford Hospital, St. John's. Newfoundland, March 10, 1997
- Advances in the pharmacotherapy of schizophrenia. Psychiatry Rounds, York-Finch Hospital, Toronto, Ontario, March 12, 1996
- Standard and novel neuroleptics: theory and clinical guidelines. Grand Rounds, Queen Street Mental Health Centre, Toronto, Ontario, March 14, 1997
- Schizophrenia I. Early detection and diagnosis, Remington G, Teehan M. Canadian Psychiatric Association 1997 International CME Program, Ixtapa, Mexico, March 18-22, 1997
- Schizophrenia II: Intervention – initiating treatment and psychosocial rehabilitation. Remington G, Beausejour P. Canadian Psychiatric Association 1997 International CME Program, Ixtapa, Mexico, March 18-22, 1997
- Phases of psychosis: acute and long-term pharmacotherapy. Department of Nursing, Clarke Institute of Psychiatry, Toronto, Ontario, March 27, 1997
- First episode psychosis: diagnosis, treatment, and the role of new antipsychotics. 'New developments in Treatment of Early Psychosis' Conference. In conjunction with the University of British Columbia and the Greater Vancouver Mental Health Services, Vancouver, British Columbia, April 8, 1997
- Assessment and management of neuroleptic-induced EPS. Prince George Regional Hospital, Prince George, British Columbia, April 9, 1997
- Schizophrenia: new theories and novel antipsychotics. Prince George Regional Hospital, Prince George, British Columbia, April 9, 1997
- Advances in the pharmacotherapy of schizophrenia. Grand Rounds, Whitby Mental Health Centre, Whitby, Ontario, April 18, 1997
- Schizophrenia: new theories and novel antipsychotics. Psychiatry Meeting, Guelph, Ontario, April 23, 1997
- Early Intervention in Schizophrenia Symposium, Chair, Toronto, May 30, 1997
- Assessment, diagnosis and early intervention in schizophrenia. 3rd Annual Schizophrenia Conference, Riverview Hospital, Port Coquitlam, British Columbia, June 4, 1997
- Schizophrenia: new theories and novel antipsychotics. Victoria '97 Schizophrenia Conference, Victoria, British Columbia, June 5, 1997
- Pharmacotherapy of schizophrenia: practical guidelines. Workshop, Victoria '97 Schizophrenia Conference, Victoria, British Columbia, June 5, 1997
- Phases of psychosis: pharmacological management.
- (i) Selkirk Mental Health Centre, Winnipeg, Manitoba, June 12, 1997
 - (ii) Winnipeg Health Sciences Centre, Department of Psychiatry, Winnipeg, Manitoba, June 12, 1997
 - (iii) Department of Psychiatry, St. Boniface, Winnipeg, Manitoba, June 12, 1997
 - (iv) Psychiatry Rounds, Grey Nuns Hospital, Edmonton, Alberta, June 13, 1997
 - (v) Psychiatry Rounds, Mesericordia Hospital, Edmonton, Alberta, June 13, 1997
 - (vi) Alberta Hospital, Ponaka, Alberta, June 13, 1997
- Advances in the pharmacology of schizophrenia. Toronto, Ontario, June 17, 1997
- Novel versus conventional neuroleptics: do they differ clinically? Development of New Chemical Entities for Schizophrenia. Saint-Jean-Cap-Ferrat, France, June 20-21, 1997
- Newer antipsychotics in the treatment of schizophrenia: clinical update on olanzapine. Queen Street Mental Health Centre, Toronto, Ontario, July 10, 1997
- Advances in the pharmacotherapy of schizophrenia. Oshawa General Hospital, Oshawa, Ontario,

- August 13, 1997
- New developments in the psychopharmacological treatment of schizophrenia. Psychiatry Research Seminars, The Toronto Hospital, Toronto, Ontario, September 22, 1997
- Pharmacotherapy of schizophrenia: practical guidelines.
- (i) Grand Rounds, Douglas Hospital, Montreal, Quebec, September 25, 1997
 - (ii) Grand Rounds, Montreal General Hospital, Montreal, Quebec, September 26, 1997
 - (iii) Psychiatry Rounds, Jewish General Hospital, Montreal, Quebec, September 26, 1997
- Will novel antipsychotics be the next standard of care for patients with schizophrenia? 2. Pharmacotherapy of first episode psychosis. 3. Long-term treatment of schizophrenia: theory and clinical practice. Schizophrenia – Looking into the Next Millennium, Vilnius, Lithuania, October 16, 1997
- Schizophrenia update. Sault Area Hospitals, Department of Psychiatry, Sault, Ste. Marie, Ontario, October 22, 1997
- Advances in the psychopharmacology of schizophrenia. North Bay Psychiatric Hospital, North Bay, Ontario, October 23, 1997
- The pharmacological treatment of schizophrenia. Schizophrenia Days 1997, Stavanger, Norway, November 7, 1997
- Clinical guidelines for schizophrenia: a Canadian perspective. Clinical Guidelines and Psychiatry: The American and Canadian Perspectives, Montreal, Quebec, November 14, 1997
- Assessment and management of neuroleptic-induced EPS, XVIIIe Congrès Annuel – Société de Psychogériatrie du Québec, Hôpital Ste-Anne, Montreal, Quebec, September 5, 1997
- Standard and novel neuroleptics: theory and clinical guidelines. Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, December 11, 1997
- The pharmacology of atypical antipsychotics. Schizophrenia Update, Toronto, Ontario, January 31, 1998
- Clinical issues in treatment resistance schizophrenia. Treatment Resistance Schizophrenia: Diagnosis and Management, North Bay, Ontario, February 6, 1998
- New developments in the psychopharmacological treatment of schizophrenia.
- (i) St. Mary's Hospital, Montreal, Quebec, February 12, 1998
 - (ii) Douglas Hospital, Montreal, Quebec, February 12, 1998
 - (iii) Montreal General Hospital, Montreal, Quebec, February 12, 1998
- Comparison of novel antipsychotics. Toronto, Ontario, February 28, 1998
- Standard and novel neuroleptics: theory and clinical guidelines.
- (i) Riverview Hospital, Port Coquitlam, British Columbia, March 11, 1998
 - (ii) Vancouver, British Columbia, March 11, 1998
- Novel agents in schizophrenia. Schizophrenia Update '98, Scottsdale, Arizona, March 28, 1998
- Current issues in the pharmacotherapy of schizophrenia. Schizophrenia: Improving Functional Outcome, Toronto, Ontario, April 2, 1998
- Assessment of movement disorders. Workshop presented at Schizophrenia: Improving Functional Outcome, Toronto, Ontario, April 2, 1998
- Issues in the acute and long-term pharmacotherapy of schizophrenia. Peterborough, Ontario, April 8, 1998
- Standard and novel neuroleptics: theory and clinical guidelines. London, Ontario, April 14, 1998
- New antipsychotic agents. Mississauga, Ontario, April 21, 1998
- Pharmacology of atypical antipsychotics. Department of Psychiatry, York County Hospital,

- Newmarket, Ontario, May 2, 1998
- First episode psychosis: the role of novel antipsychotics. International Delegates Program, American Psychiatric Association 151st Annual Meeting, Toronto, May 30 – June 4, 1998
- Will novel antipsychotics be the next standard of care in schizophrenia? Treatment strategies in the management of schizophrenia.
- (i) Istanbul, Turkey, June 15, 1998
 - (ii) Izmir, Turkey, June 16, 1998
 - (iii) Bakirkoy Mental Hospital, Istanbul, Turkey, June 17, 1998
- Antipsychotics: exploration of the novel antipsychotics. Program of Advances Psychopharmacology of Psychiatrists. Clarke Institute of Psychiatry, Toronto, Ontario:
- (i) June 24, 1998
 - (ii) January 27, 1999
- Pharmacotherapy in schizophrenia – an update. Schizophrenia 98: Identification, Intervention and Pharmacotherapy. Waterford Hospital, St. John's, Newfoundland, September 25, 1998
- Decision making in clinical use of antipsychotics (workshop). Schizophrenia 98: Identification, Intervention and Pharmacotherapy. Waterford Hospital, St. John's, Newfoundland, September 25, 1998
- Pharmacotherapy in the early stages of psychosis. NATO Advanced Research Workshop: Early Intervention on Psychiatric Disorders. Prague, Czech Republic, October 22 –27, 1998
- Pharmacotherapy of first episode schizophrenia. Bulgarian Psychiatric Association Annual Meeting, Sofia, Bulgaria, November 6 – 8, 1998
- Psychosis and the new antipsychotic. General Psychiatry for Family Physicians (GFPF) Seminar Series 1998/99, Centre for Addiction and Mental Health, The Clarke, Toronto, Ontario, November 18, 1998
- New developments in the psychopharmacologic treatment of schizophrenia.
- (i) Medical Staff Quarterly Meeting, Queensway Carleton Hospital, Ottawa, Ontario, December 7, 1998
 - (ii) Psychiatric Rounds, Queensway Carleton Hospital, Ottawa, Ontario, December 8, 1998
 - (iii) Grand Rounds, Royal Ottawa Hospital, Ottawa, Ontario, December 8, 1998
- Long-acting antipsychotics and the role of the depot clinic. Conference, Difficult to Serve Psychiatric Populations: Aspects of Community Care. North Bay, Ontario, February 11-12, 1999
- Clozapine vs risperidone in refractory schizophrenia. Maximizing Optimum Treatment in the Expanding Age of Treatment Resistant Schizophrenia. St.-Sauveur, Quebec, February 26 – 28, 1999
- Pharmacotherapy of schizophrenia: an update.
- (i) Edmonton, Alberta, March 9, 1999
 - (ii) Psychiatry Rounds, Alberta Hospital, Ponoka, Alberta, March 10, 1999
 - (iii) Red Deer, Alberta, March 10, 1999
 - (iv) Psychiatry Rounds, University of Saskatchewan, Regina, Saskatchewan, March 11, 1999
 - (v) Psychiatry Rounds, University of Saskatchewan, Saskatoon, Saskatchewan, March 12, 1999
- Assessment and treatment of neuroleptic-induced EPS. Whitby Mental Health Centre. Whitby, Ontario, March 26, 1999
- Addressing compliance to optimize clinical outcome. A Patient-Based Learning Program in

- Schizophrenia and Related Psychotic Disorders. Toronto, Ontario, March 27, 1999
- Conventional and novel antipsychotics: theoretical and clinical guidelines. Mental Health Services, Brantford, Ontario, April 28, 1999
- Antipsychotics and schizophrenia: from science to clinical practice. Grand Rounds, Department of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, Ontario, May 12, 1999
- Addressing compliance to optimize clinical outcome. A Patient-Based Program in Schizophrenia and Related Psychotic Disorders. Ottawa, Ontario, June 11-12, 1999
- What is a novel antipsychotic? Novel Antipsychotics in the New Millennium. State University of New York (SUNY), Syracuse, New York, August 26, 1999
- New insights into the pharmacotherapy in early schizophrenia. Search for Treatments in Early Psychosis (STEP): Second Biennial Symposium, University of Pittsburgh, Pittsburgh, Pennsylvania, September 10, 1999
- Pharmacotherapy of schizophrenia: from first episode to refractory. Psychopharmacology Update 1999 (sponsored by the Canadian Psychiatric Association). Canadian Psychiatric Association 49th Annual Meeting, Toronto, Ontario, September 14-18, 1999
- Optimizing treatment in schizophrenia. Update for Mental Health Care providers. Brandon, Manitoba, September 23, 1999
- The psychopharmacology of schizophrenia: where are we? Conference, Real Problems, Real Solutions. Winnipeg, Manitoba, September 24, 1999
- Assessment and management of neuroleptic-induced movement disorders. Centre for Addiction and Mental Health, Toronto, Ontario, September 29, 1999
- From the lab to clinical practice: what have we learned? Conference, Psychosis: Integrating Research, Education and Clinical Practice to Optimize Outcomes. Third Annual Atlantic Canada Psychosis Conference, Halifax, Nova Scotia, October 1, 1999
- A systematic approach to the pharmacotherapy of psychosis (workshop). Conference, Psychosis: Integrating Research, Education and Clinical practice to Optimize Outcomes. Third Annual Atlantic Psychosis Conference, Halifax, Nova Scotia, October 1, 1999
- Antipsychotics: from the lab to clinical practice. Grand Rounds, St. Michael's-Wellesley Hospitals, Toronto, Ontario, November 5, 1999
- Pharmacotherapy of schizophrenia: from the lab to clinical practice. Conference, Credit Valley Update: Schizophrenia 1999, Mississauga, Ontario, December 10, 1999
- Optimizing treatment in schizophrenia (workshop). Conference, Credit Valley Update: Schizophrenia 1999, Mississauga, Ontario, December 10, 1999
- Antipsychotic treatment in schizophrenia: where are we? Grand Rounds, Department of Psychiatry, St. Joseph's Hospital, Toronto, Ontario, January 18, 2000
- Antipsychotics: Exploration of the novel antipsychotics. Toronto Advanced Psychopharmacology for Psychiatrists (TAPP), Centre for Addiction and Mental Health, Toronto, Ontario, January 26, 2000
- Pharmacotherapy of schizophrenia: integrating theory and clinical practice. Psychiatry Grand Rounds, Oakville-Trafalgar Hospital, Oakville, Ontario, February 10, 2000
- Pharmacotherapy of schizophrenia: where are we? A Problem Based Learning Program in Schizophrenia and Related Psychotic Disorders. Halifax, Nova Scotia, February 12, 2000
- Optimizing treatment in chronic schizophrenia. A Problem Based Learning Program in Schizophrenia and Related Psychotic Disorders.
- (i) Halifax, Nova Scotia, February 12, 2000
 - (ii) Toronto, Ontario, February 26, 2000
- Conventional versus novel antipsychotics: changing concepts and clinical implications

- (i) Kanazawa University, Kanazawa, Japan, April 7, 2000
 - (ii) Hiroshima University, Hiroshima, Japan, April 8, 2000
- New treatment options for first episode psychosis. Symposium, Recent Changes in First Episode Psychosis. 3rd International Congress of Neuropsychiatry (ICN), Kyoto, Japan, April 9-14, 2000
- Current issues in the pharmacotherapy of schizophrenia. Department of Psychiatry, Credit Valley Hospital, Mississauga, Ontario, May 3, 2000
- Antipsychotics: from theory to clinical practice. Psychosis: Then and Now. Woodstock, Prince Edward Island, August 12, 2000
- Practical issues in long-term antipsychotic use. Workshop, Psychosis: Then and Now. Woodstock, Prince Edward Island, August 12, 2000
- Antipsychotics: integrating theory and clinical practice. Royal Ottawa Hospital, Ottawa, Ontario, September 19, 2000
- The pharmacotherapy of schizophrenia: making sense of science. 17th Annual Garwood-Jones Lecture, Department of Psychiatry, McMaster University, Hamilton, Ontario, October 11, 2000
- Antipsychotics: from PET to clinical practice. Psychiatry Rounds, Wellesley Hospital, Toronto, Ontario, October 13, 2000
- Antipsychotic use in the clinical setting. 3rd Annual Ontario Assertive Community Treatment (ACT) Conference, Kingston, Ontario, October 18-20, 2000
- Antipsychotics: integrating theory and clinical practice. Department of Psychiatry, McGill University, Montreal, Quebec, November 2, 2000
- Psychosis and the new antipsychotics. Primary Care General Psychiatry Course (PCGPC), Centre for Addiction and Mental Health, Toronto, Ontario, November 15, 2000
- PET scan and clinical findings with the typical and atypical antipsychotics. Department of Psychiatry, Hotel-Dieu de Lévis, Quebec City, Quebec, November 22, 2000
- Novel antipsychotics: are they doing better on EPS? Department of Psychiatry, Centre Hospitalier Universitaire Laval, Quebec City, Quebec, November 23, 2000
- Antipsychotics: exploration of the novel antipsychotics. Toronto Advanced Psychopharmacology for Psychiatrists (TAPPS), Centre for Addiction and Mental Health, Toronto, Ontario, January 17, 2001
- Improving outcome: the role of medication compliance. New Thinking, New Dialogue: An Interactive Program on Schizophrenia and Bipolar Disorder.
- (i) Hockley Valley, February 23-25, 2001
 - (ii) Toronto, March 30-April 1, 2001
 - (iii) Collingwood, June 8-10, 2001
- Treatment of refractory schizophrenia. Toronto Psychopharmacology Update Day, Centre for Addiction and Mental Health, Toronto, Ontario, March 10, 2001
- Antipsychotics: integrating theory and clinical practice. Psychopharmacology Rounds, Centre Hospitalier Louis H. Lafontaine, Montreal, Quebec, March 26, 2001
- The pharmacotherapy of schizophrenia: what's new? Symposium, Best Practice Guidelines in the Treatment of Schizophrenia. Health Care in a Complex World: an International Research Conference, Toronto, Ontario, May 2-4, 2001
- Augmentation strategies. Ontario Government Pharmaceutical and Medical Supply Service: Pharmacists' Seminar 2001, Toronto, Ontario, May 16-17, 2001
- Update on the management of schizophrenia – what's on the horizon? The 8th Malaysian Conference on Psychological Medicine. Kuala Lumpur, Malaysia, June 22-24, 2001
- Understanding antipsychotics: from PET to clinical practice. Woodbridge Hospital, Singapore,

- June 25, 2001
- Emerging theories on dopamine binding and the selection of antipsychotic agents. Presentation with Dr. P. Seeman. PsychLINK, Dallas, Texas, July 11, 2001
- DSM-IV and the clinical interview. Graduate Seminar in Social Work. Ontario Institute for Studies in Education (OISE), Toronto, Ontario, September 17, 2001
- Current antipsychotic use: integrating PET and clinical data. Department of Psychiatry Residents' Retreat, University of Alberta, Calgary, Alberta, September 19, 2001
- Fifty years of antipsychotic experience: an update. Claresholm Hospital, Claresholm, Alberta, September 22, 2001
- PET, D₂ receptors, and antipsychotic activity: what have we learned?
- (i) Department of Psychiatry Rounds, Foothills Hospital, Calgary, Alberta, September 21, 2001
 - (ii) Department of Psychiatry Rounds, Lougheed Medical Centre, Calgary, Alberta, September 21, 2001
- Update on schizophrenia. Dr. F. Jensen Memorial Lecture, A Day in Psychiatry IX (co-sponsored by Department of Psychiatry, University of Western Ontario), Stratford, Ontario, September 28, 2001
- Interventions and outcomes: the many faces of schizophrenia. Saskatchewan Schizophrenia 2001 Conference. Department of Psychiatry, University of Saskatchewan, and Schizophrenia Society of Saskatchewan, Saskatoon, Saskatchewan, October 15, 2001
- Improving outcome: clinical considerations (workshop). Saskatchewan Schizophrenia 2001 Conference. Department of Psychiatry, University of Saskatchewan, and Schizophrenia Society of Saskatchewan, Saskatoon, Saskatchewan, October 15, 2001
- From the PET lab to the clinic: implications for antipsychotic activity. Psychopharmacology Update, Waterford, Ireland, November 10, 2001
- Antipsychotics: exploration of the novel antipsychotics. Toronto Advanced Psychopharmacology for Psychiatrists (TAPPS), Centre for Addiction and Mental Health, Toronto, Ontario, January 30, 2002
- Treatment resistant psychosis. Clinical Challenges in Psychiatric Practice (CCPP), Centre for Addiction and Mental Health, Toronto, Ontario, February 12, 2002
- 'Atypicality', dopamine and serotonin: different means to the same end?
- (i) Grand Rounds, Douglas Hospital, Montreal, Quebec, February 14, 2002
 - (ii) Grand Rounds, Montreal General Hospital, Montreal, Quebec, February 15, 2002
- What to do in partial responders. Symposium, Treatment-Resistant Schizophrenia. Annual Quebec Psychiatric Association (AMPQ) Meeting, Mont-Tremblant, Quebec, June 6-9, 2002
- Translating evidence-based medicine into everyday clinical practice. Symposium, New Directions in Antipsychotic Therapy. XXIII Collegium Internationale Neuro-psychopharmacologicum (CINP), Montreal, Quebec, June 23-27, 2002
- Treatment-resistant schizophrenia. ACT Team Psychiatrists, Toronto, Ontario, July 5, 2002
- The antipsychotic effect – what is it based upon? Schizophrenia Update, Oslo, Norway, September 14, 2002
- Schizophrenia and treatment-resistance. Grand Rounds, Whitby Mental Health Centre, Whitby, Ontario, September 20, 2002
- Rational psychopharmacology in early psychosis. 3rd International Conference on Early Psychosis. Copenhagen, Denmark, September 25-28, 2002
- The use of antipsychotics in early psychosis. First Episode Psychosis Symposium, Sault Saint Marie, October 4, 2002

- Best practice in pharmacological management of first episode psychosis. Workshop, First Episode Symposium, Sault Saint Marie, October 4, 2002
- PET and the use of typical and atypical antipsychotics. Symposium: Treatment of the Spectrum of Psychoses. Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002
- Tardive dyskinesia: a phantom of the past? Symposium: Treatment of the Spectrum of Psychoses. Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002
- Remington G. Antipsychotics: atypicality and mechanisms of action. Plenary Lecture, Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002
- Cetkovich M, Crow T, Fleischhacker W, Gaebel W, Duran E, Pfulmann B, Remington G. The prodrome of schizophrenia: to treat or not to treat? Debate, Regional Congress of the World Federation of Societies of Biological Psychiatry, Santiago, Chile, November 20-23, 2002
- What's 'atypical' about the new antipsychotics? Neuropsychiatry Rounds, University Hospital Network, Toronto Western Hospital, November 28, 2002
- Antipsychotics once a day? Theory and evidence. 8th Annual Psychopharmacology Update, Nevada Psychiatric Association, February 13, 2003
- How does mechanism of action relate to clinical effectiveness and patient outcomes. Distant Learning Network (DLN) and University of Florida, Cincinnati, Ohio, March 4, 2003
- Long-acting depot antipsychotics: where do they fit in? Auckland, New Zealand, March 19, 2003
- Novel antipsychotics in depot formulation: research experience and practical considerations. Modern Management of Psychosis, Sydney, Australia, March 21, 2003
- Mothers, molecules and madness. Annual Oklahoma Psychiatric Association Meeting. Oklahoma City, Oklahoma, April 12-14, 2003
- The concept of 'atypicality' and its clinical implications. Annual Oklahoma Psychiatric Association Meeting. Oklahoma City, Oklahoma, April 12-14, 2003
- Enhancing antipsychotic effectiveness. Schizophrenia Research Foundation (SCARF), Chennai, India, May 7, 2003
- Re-defining the pharmacological definition of 'atypicality'. Symposium, Clinical Effectiveness – What Does It Mean and What's New. San Francisco. California, May 20, 2003
- Antipsychotics 50 years later: what have we learned? Professorial Lecture, Department of Psychiatry, University of Toronto, Toronto, Ontario, June 10, 2003
- The concept of 'atypicality': integrating PET data with clinical practice.
- (i) Brecksville VA, Brecksville, Ohio, June 17, 2003
 - (ii) Cleveland Clinic, Cleveland, Ohio, June 18, 2003
 - (iii) Bridgeway Community Mental Health Clinic, Cleveland, Ohio, June 19, 2003
- Antipsychotics 50 years later: what have we learned? Grand Rounds, Toronto General Hospital, Toronto, Ontario, September 19, 2003
- Schizophrenia and its prodrome. Sagamore Children's Centre, Suffolk County, New York, September 23, 2003
- The concept of 'atypicality': integrating PET data with clinical evidence. Department of Psychiatry Grand Rounds, The Zucker Hillside Hospital, Glen Oaks, New York, September 24, 2003
- The early years of schizophrenia. St. Mary's Children and Family Services, Syosset, New York, September 25, 2003
- The evolution of schizophrenia. Department of Psychiatry, Royal Ottawa Hospital, Ottawa,

- Ontario, October 1, 2003
- Antipsychotics: from PET to clinical practice. Royal Ottawa Hospital, Ottawa, Ontario, October 1, 2003
- Antipsychotics: integrating theory with clinical practice. Grand Rounds, Department of Psychiatry, Sunnybrook Hospital, October 10, 2003
- Antipsychotics 50 years later: what have we learned? Grand Rounds, Department of Psychiatry, Mount Sinai Hospital, October 17, 2003
- Antipsychotics: mechanisms of action and new treatments. Toronto Advanced Psychopharmacology Course for Psychiatrists, Centre for Addiction and Mental Health, Toronto, Ontario, October 22, 2003
- From response to refractory: the evolution of schizophrenia and its pharmacotherapy. Associations des médecins psychiatres du Quebec. Psychopharmacology Update, Quebec City, Quebec, November 27-29, 2003
- The science behind placebo-controlled trials: research methodology and clinical trial design. National Judicial Institute Conference, Research and the Law: A Working Conversation on Scientific Research in the Courtroom. Toronto, Ontario, February 22-24, 2004
- Antipsychotic 'atypicality': a clinical and moving pharmacological target. Academic Grand Rounds, Allan Memorial Institute, Montreal, Quebec, April 15, 2004
- Antipsychotics: a clinical update. Grand Rounds, Whitby Mental Health Centre, Whitby, Ontario, September 24, 2004
- Antipsychotic use: merging theory and science with clinical practice. 10th Annual Conference of the Canadian Academy of Psychiatry and the Law (CAPL). Mont Tremblant, Quebec, February 27-March 2, 2005
- Antipsychotic 'atypicality': is it just a dopamine story? 8th Annual Meeting, College of Psychiatric and Neurologic Pharmacists, San Diego, California, March 10-13, 2005
- First episode schizophrenia: what do we know? 8th Annual Meeting, College of Psychiatric and Neurologic Pharmacists, San Diego, California, March 10-13, 2005
- Antipsychotics and dopamine: from receptors to response. Schizophrenia Forum, Oslo, Norway, September 9, 2005
- Antipsychotics and schizophrenia 50 years later: what have we learned? Mental Health Grand Rounds, Humber River Regional Hospital, October 14, 2005
- Wesson V, Remington G. The CATIE study: results and implications for clinical practice. CAMH Grand Rounds, Toronto, Ontario, October 28, 2005
- Adverse event reporting. Conference, Pharmaceutical Research – Review Board and Institutional Challenges, Toronto, Ontario, Nov 4-5, 2005
- Treatment of schizophrenia in the community. Conference, Waterford Day. Caring for the Chronic Patient in the Community: Clinical and Ethical Issues. St. John's, Newfoundland, November 18, 2005
- Bottas A, Remington G. Dissecting the CATIE schizophrenia study. Whitby Mental Health Centre, Whitby, Ontario, November 30, 2005
- Refractory schizophrenia. Toronto Advanced Psychopharmacology Course for Psychiatrists, Centre for Addiction and Mental Health, Toronto, Ontario, December 7, 2005
- Chintoh A, Mann S, Remington G. Schizophrenia, antipsychotics, and weight gain/diabetes. Schizophrenia Program Research Rounds, Centre for Addiction and Mental Health, Toronto, Ontario, December 14, 2005
- Schizophrenia and antipsychotics 50 years later: what have we learned. Psychiatry Grand Rounds, University Health Network, Toronto, Ontario, November 3, 2006
- Refractory schizophrenia. Toronto Advanced Psychopharmacology Course for Psychiatrists,

- Centre for Addiction and Mental Health, Toronto, Ontario, December 6, 2006
- Antipsychotics 50 years later: what have we learned? Department of Psychiatry Rounds, University of Ottawa, January 19, 2007
- Update on schizophrenia, its conceptualization, and treatment. Resident Seminar, University of Ottawa, January 19, 2007
- Foussias G, Remington G. Was Kraepelin right? Revisiting the negative symptoms of schizophrenia. Grand Rounds, CAMH, February 2, 2007
- Antipsychotics 50 years later: what have we learned? Clinical Neurosciences 2007 Conference, University of British Columbia, Vancouver, BC, February 23, 2007
- Remission in schizophrenia – a false hope? Clinical Neurosciences 2007 Conference, University of British Columbia, Vancouver, BC, February 23, 2007
- Antipsychotics 50 years later: what have we learned? Ontario Working Group on Early Intervention in Psychosis Conference. Toronto, Ontario, March 2, 2007
- Bridging evidence, theory, and clinical experience to optimize antipsychotic response. Grand Rounds, H
omewood Hospital, Guelph, Ontario, May 29, 2007
- Antipsychotics 50 years later: what have we learned? World Fellowship for Schizophrenia and Allied Disorders, 2007 International Conference – Lighting the Path: Hope in Action. Toronto, Ontario, September 29, 2007
- The pharmacotherapy of schizophrenia – what have we learned and where do we go? Innovative Horizons: 15th Annual Schizophrenia Conference, Edmonton, Alberta, October 5, 2007
- The pharmacotherapy of schizophrenia: do all roads lead to dopamine? Institute of Mental Health Research Rounds, Ottawa, Ontario, November 2, 2007
- From Psychology/Biology 101 to the pharmacology of schizophrenia. Plenary lecture, Laurier Student Science Awards 2008, Wilfrid Laurier University, Waterloo, Ontario, February 4, 2008
- Ziprasidone: Canada's newest 'atypical' antipsychotic. Remington G, Cohn T. CAMH Grand Rounds, Toronto, Ontario, February 29, 2008
- Deconstructing schizophrenia: implications for treatment. Plenary lecture, Alberta Psychiatric Association, Banff, Alberta, April 4-6, 2008
- Clozapine-resistant schizophrenia. Grand Rounds, Whitby Mental Health Centre, Whitby, Ontario, April 25, 2008
- Psychopharmacology of schizophrenia (workshop). Schizophrenia 2008 Update, Toronto, Ontario, October 3, 2008
- Antipsychotics and glucose dysregulation: from animal models to model animals. Research Rounds, Mood Disorders Program, CAMH, October 16, 2008
- Schizophrenia pharmacotherapy: challenges and opportunities. Grand Rounds, McMaster University, Hamilton, Ontario, May 27, 2009
- Schizophrenia, dopamine and L-dopa. Multimodal Imaging Group Research Rounds, CAMH, Toronto, Ontario, January 13, 2010
- Schizophrenia and functional outcome. National Workshop, Office of the Commissioner of Review Tribunals. Canada Pension Plan (CPP)/Old Age Security (OGA), Toronto, Ontario September 28, 2010
- First episode psychosis: presentation, treatment and outcome. Grand Rounds, Department of Psychiatry, Moncton Hospital, September 30, 2010
- Antipsychotic pharmacotherapy: from evidence to clinical practice. Grand Rounds, Department of Psychiatry, George Dumont Hospital, October 1, 2010
- Schizophrenia and functional outcome. National Workshop, Office of the Commissioner of

- Review Tribunals. Canada Pension Plan (CPP)/Old Age Security (OGA), Ottawa, Ontario, October 19, 2010
- Antipsychotic algorithms. Grand Rounds, Department of Health and Rehabilitation, Hospital Center Division, Essex County Health Center, New Jersey, USA, October 21, 2010
- Antipsychotics a half-century later: still a work in progress. 8th Atlantic Canada Psychosis Conference, Halifax, Nova Scotia, November 5, 2010
- Antipsychotics: linking theory with clinical practice (workshop). 8th Atlantic Canada Psychosis Conference, Halifax, Nova Scotia, November 5, 2010
- Ask the Experts – Antipsychotics. Schizophrenia Update Conference, Toronto, Ontario, November 26, 2010
- Schizophrenia a century later: still a work in progress. Schizophrenia Society of Ontario, Annual Staff Meeting, Toronto, Ontario, December 9, 2010
- Treating schizophrenia across the lifespan. Psychiatry Grand Rounds, Humber Regional Hospital, Toronto, Ontario, April 115, 2011
- The prodrome of schizophrenia and first episode psychosis: treatment outcomes. Moncton Hospital, Department of Psychiatry, Grand Rounds, Moncton, New Brunswick, June 2, 2011.
- Treatment algorithms in schizophrenia: challenges and opportunities. Psychiatry Rounds, Charlottetown, Prince Edward Island, June 3, 2011.
- Schizophrenia and antipsychotics: linking theory and clinical practice. Psychiatry Rounds, Grey-Bruce Health Centre, Owen Sound, Ontario, June 17, 2011
- Rodent models: a viable option? Adipogenic and Metabolic Effects of Antipsychotic Drugs (sponsored by NIH and University of Alabama Nutrition and Obesity Research Center), Newark, New Jersey, July 11-12, 2011
- Remington G, Wong A. First vs. second generation antipsychotics: pros and cons. Psychopharmacology Seminar, CAMH, Toronto, September 21, 2011
- Schuchman M, Remington G. Human subject research in psychotic individuals: is it ethical? Joint Centre for Bioethics, University of Toronto, Toronto, Ontario, September 21, 2011
- Remington G, Richards S. Facilitating clinical trials. Conference - Getting to Yes: Facilitating Ethical Human Research. Centre for Addiction and Mental Health, Toronto, Ontario, September 21, 2011
- Reconceptualizing schizophrenia: pharmacological challenges and opportunities. Plenary Lecture, Psychosis Day, Department of Psychiatry, University of Calgary. Calgary, Alberta, October 21, 2011
- Antipsychotics: optimizing clinical outcome. Workshop, Psychosis Day, Department of Psychiatry, University of Calgary. Calgary, Alberta, October 21, 2011
- Remington G, Powell V. 20 years of clozapine: what have we learned? Schizophrenia Research Day, CAMH, Toronto, Ontario, October 26, 2011
- Reconceptualizing schizophrenia: implications for treatment. Grand Rounds, University Hospital Network (Toronto General), Department of Psychiatry. Toronto, Ontario, November 4, 2011
- Psychopharmacology for schizophrenia: lessons from neuroscience (Plenary Lecture). Toronto Psychopharmacology Day, Toronto, Ontario, March 10, 2012
- Antipsychotic dosing: found in translation? Innovations in Neuropsychopharmacology Award Lecture. Canadian College of Neuropsychopharmacology, Vancouver, British Columbia, March 24-March 26, 2012
- Extended antipsychotic dosing: rationale and clinical findings. Dr. John C. Corrigan Mental Health Center/West Roxbury-Brockton Veterans Administration Medical Center,

- Department of Psychiatry, Harvard University, United States. May 31, 2012
- Antipsychotics and schizophrenia. Schizophrenia Program Resident Seminar, CAMH, Toronto, Ont, July 12, 2012
- Schizophrenia and antipsychotics. Resident Seminar, Schizophrenia Program. CAMH, July 7, 2012
- First versus second generation antipsychotics (Albert Wong, Gary Remington). Resident Psychopharmacology Seminar. CAMH, Sept 19, 2012
- Schizophrenia. IMS Graduate Course MSC 1089Y, The Biopsychosocial Basis of Mental Health and Addictive Disorders, University of Toronto. CAMH, Toronto, Sept 27, 2012
- Antipsychotics: linking theory with clinical practice. Cleveland Clinic, Department of Psychiatry and Psychology Grand Rounds. Cleveland, Ohio, Oct 4, 2012
- Update on schizophrenia and antipsychotics. PGY-5 Seminar Series, Department of Psychiatry, University of Toronto, Toronto, Oct 10, 2012
- Schizophrenia and antipsychotics: an update. Canadian Mental Health Association (CMHA), Brampton, Ontario, Nov 9, 2012
- Schizophrenia and antipsychotics: linking theory and clinical practice. Plenary lecture, Victoria and Vancouver Island Schizophrenia Conference, Victoria, British Columbia, November 16, 2012
- From first episode to refractory schizophrenia: optimizing pharmacotherapy. Workshop, Victoria and Vancouver Island Schizophrenia Conference, Victoria, British Columbia, November 16, 2012
- Patterns of antipsychotic nonadherence. Reducing the Burden of Chronic Disease in Canada: Innovative Approaches to Disease Management Within Primary Care. Collaborative Forum, CIHR and Pfizer Canada. Ottawa, Ont, Nov 20, 2012
- Screening for extrapyramidal side effects. Workshop, Ontario Pharmacists Association: Psychiatric Patient Care Conference, Toronto, Ont, Nov 30-Dec 2, 2012
- Antipsychotic dosing: answers found in translation. State University of New York (SUNY) at Buffalo, Grand Rounds, Buffalo, New York, USA, Dec 7, 2012
- Subtyping schizophrenia: implications for pathophysiology and treatment. Canadian Association of Psychiatry and the Law (CAPL) Annual Winter Meeting, Mont Tremblant, Quebec, March 4, 2013
- Algorithm-based treatment for first-episode schizophrenia. Regina, Saskatchewan, June 12, 2013
- Use of treatment response to establish schizophrenia subtypes. Edmonton, Alberta, June 13, 2013
- The pharmacology of antipsychotics. University of Toronto, Department of Pharmacy, Year III Lecture Series, Toronto, Ontario, Sept 17, 2013
- First versus second generation antipsychotics. Albert Wong, Gary Remington: Resident Psychopharmacology Seminar. CAMH, Sept 18, 2013
- When in doubt, look at the evidence: investigating high doses and combination treatment strategies in schizophrenia. Bill Honer, Sumeet Singh, Gary Remington: Symposium, Canadian Psychiatric Association 63rd Annual Meeting, Ottawa, Ontario, September 26, 2013
- Remington G, Fellus J. Novel CNS drugs. Cowen and Co., 16th Annual Therapeutics Conference. New York, NY, October 8, 2013
- Remington G, Chaiet A, Davies S. Antipsychotic polypharmacy: rational or irrational. CAMH Grand Rounds, Toronto, October 10, 2013
- Remington G. Redefining schizophrenia: DSM-V and other new diagnostic approaches. Grand Rounds, Homewood Health Centre, Guelph, October 31, 2013
- Remington G. Antipsychotics a half-century later: still a work in progress. Schizophrenia

- Program Seminar Series, CAMH, Toronto, February 26, 2014
- Remington G. Redefining schizophrenia: DSM-V and other new diagnostic approaches. Psychiatry Rounds, Rouge Valley Centenary Hospital, Toronto, February 26, 2014
- Remington G. Best practices for antipsychotic use. Ontario Psychiatric Association 2014 Annual Conference, Toronto, March 22, 2014
- Remington G. Best practices for antipsychotic use. Department of Psychiatry PGY5 Review Seminar Series, Toronto, September 17, 2014
- Remington G. Highlighting schizophrenia's heterogeneity to personalize treatment (Plenary). The 8th Annual Pacific Psychopharmacology Conference. Vancouver, British Columbia, September 19, 2014
- Remington G. Schizophrenia and its pharmacotherapy. University of Toronto Institute of Medical Science (IMS) 1089H Course, Toronto, September 25, 2014
- Remington G. A comparison across two generations of antipsychotics. Department of Psychiatry PGY2 Psychopharmacology Seminar Series, CAMH, Toronto, October 1, 2014
- Remington G, Wong A. A comparison across two generation of antipsychotics (Part 2). Department of Psychiatry PGY2 Psychopharmacology Seminar Series, CAMH, Toronto, October 8, 2014
- Remington G. Antipsychotics. CAMH Psychopharmacology Seminar Series, CAMH, Toronto, October 16, 2014
- Remington G. Antipsychotic update. Professional Specialty Group in Drug Use Evaluation (PSG-DUE). Toronto, Ontario, March 5, 2015
- Remington G. Pharmacotherapy in schizophrenia. IMS MSc 10881H - Studies in Schizophrenia, March 25, 2015
- Remington G. Antipsychotics: evidence and expectations. Continuing Professional Development Rounds, Department of Psychiatry, University of Western Ontario, April 9, 2015
- Remington G. Schizophrenia's heterogeneity: implications for treatment. Grand Rounds, Douglas Mental Health University Institute, Montreal, Quebec, April 16, 2015
- Remington G. Subtyping schizophrenia: implications for pathophysiology and treatment. Grand Rounds, Sacre-Coeur Hospital, Montreal, Quebec, April 17, 2015

E.3. Other

- Schizophrenia: a journey through turbulence. Schizophrenia Society of Canada, Educational Video, 1994
- New pharmacological agents. Schizophrenia: Biological, Legal & Clinical Perspectives, A Public Education Series, Schizophrenia Research Program, Clarke Institute of Psychiatry, Toronto, Ontario, April 20, 1994
- Co-director, Janssen Canadian Residents Schizophrenia Scholars Program
- American Psychiatric Association, 149th Annual Meeting, New York, New York, May 4-9, 1996
 - American Psychiatric Association, 150th Annual Meeting, San Diego, California, May 17-22, 1997
 - American Psychiatric Association, 151st Annual Meeting, Toronto, Ontario, May 30-June 4, 1999
 - American Psychiatric Association, 152nd Annual Meeting, Washington DC, May 15-20, 1999
 - American Psychiatric Association, 153rd Annual Meeting, Chicago, Illinois, May 13-18, 2000

- Public Forum, Schizophrenia – Current Research and New Treatments, Sudbury, Ontario, May 11, 1996
- Update on schizophrenia. Panel discussion – Schizophrenia Society of Alberta, Calgary, Alberta, June 3, 1996
- Co-chair, ACCESS: a national education and consultation program in psychiatry for GP/FPs, 1996-1997
- Schizophrenia: an update. FAME (Family Association for Mental Health Everywhere), Etobicoke, Ontario, April 21, 1997
- Schizophrenia: new theories and novel antipsychotics. Mens Sana – Families for Schizophrenics, Toronto, Ontario, October 7, 1997
- New horizons for schizophrenia. Canadian Mental Health Association, North Bay, Ontario, October 23, 1997
- What's new in schizophrenia research. FAME (Family Association for Mental Health Everywhere), Scarborough, Ontario, October 27, 1997
- Update on medications. Schizophrenia Society of Ontario, Scarborough Chapter, Scarborough, Ontario, April 2, 1998
- Schizophrenia: what have we learned? Public Health Forum, sponsored by Mental Health Consultation Liaison Service, Grey Bruce Health Services, Owen Sound, Ontario, March 10, 2000
- PET and schizophrenia: from the lab to clinical practice. Schizophrenia Society of Ontario, Scarborough Chapter, Scarborough, Ontario, May 3, 2000
- Schizophrenia: existing challenges, new opportunities. Schizophrenia Society of Ontario, Burlington, Ontario, May 11, 2011
- What's new in schizophrenia: a brief update. Schizophrenia Society of Ontario, Owen Sound, Ontario, June 16, 2011
- Remington G. Conceptualization and diagnosis of schizophrenia: an update. Schizophrenia Society of Ontario (SSO) Annual Board of Directors Meeting, Toronto, June 14, 2014
- Remington G. New approaches in the understanding and subtyping of schizophrenia. Schizophrenia Society of Ontario, Toronto, Ontario, September 24, 2014
- Healthy Minds Canada Taking Charge 2015: Pathways To Your Own Mental Health Conference Panel discussion: charting treatment (Chair - S Hahaim; Panelists – M Ross, J Geraci, G Remington). Toronto, Ontario, June 20, 2015

F. Teaching and Design

F.1 Undergraduate Teaching

Teaching	Years
Medical students Years I, II, and III Psychiatry rotation	1984/85 - 1997
Medical students Year I Psychiatry elective	1991/92 - 1997
Schizophrenia,	1993/94

Psychiatry Institute of Medical Students
Medical students, Year I & II

Biology of Schizophrenia,
Brain & Behaviour Course
Medical Students,
Year I 1994/95

Occupational therapy students
Year III 1985 – 1987
Psychopharmacology seminars

Pharmacy students
Year III 1985 – 1987
Schizophrenia and its treatment

F.2 Postgraduate Teaching **Teaching**

Resident supervision
Centre for Addiction and Mental Health **Years**
1984/85 - present

Clarke Institute of Psychiatry Residents –
Psychopharmacology Seminars 1984/85 – 1991/92

Core Lecture Series, PGY-I & II 1991/92 – 1997/98
(a) Psychopharmacology of Schizophrenia
(b) Neuroleptic-Induced Side Effects
Department of Psychiatry
University of Toronto

Psychopharmacology Series 1994/95 - 2004
Graduate Psychophysiology Seminar
York University

Continuing Care Division Resident Seminars
on Schizophrenia 1994/95 - present

Practical Approach to Psychopharmacology
Seminar Series: Neuroleptics (PGY-1) 1995/96

Neuroscience and Psychopharmacology Course,
PGY-I 1997/98
(a) Antipsychotics I
(b) Antipsychotics II
Department of Psychiatry
University of Toronto

Core Program Seminars, PGY-II 1997 - 2000

The psychopharmacology of schizophrenia
 Department of Psychiatry
 McMaster University

Core Curriculum Seminars, PGY-V 2002 - present

Psychosis and antipsychotics
 Department of Psychiatry
 University of Toronto

Clinical Psychopharmacology Seminars 2004 - present

CAMH Residents Program

Schizophrenia & its Psychopharmacology – 2005 – 2008

Graduate Course, Institute of Medical Science
 (IMS),
 University of Toronto

PGY-II Psychopharmacology 2009 - present

Typical vs. Atypical Antipsychotics

G. Graduate Student Supervision

Primary Supervisor – Fellows

Name: Siow-Ann Chong
 Program: Department of Psychiatry
 Woodbridge Hospital
 Singapore
 Degree: Postdoctoral Research Fellowship
 Title: Ethnocultural factors in antipsychotic metabolism and clinical
 response
 Years: 1997-1998

Name: Muhammad Fadzillah Abdul Razak
 Program: Department of Psychiatry
 Hospital Kuala Lumpur
 Jalan Pahang, Malaysia
 Degree: Postdoctoral Research Fellowship
 Title: Antipsychotic dosing strategies based on D₂ transience
 Years: 2002 – 2003

Name: Naren Rao (Co-Supervisor with Dr. Romina Mizrahi)
 Program: National Institute of Mental Health and Neurosciences
 Bangalore, India
 Degree: Postdoctoral Research Fellowship
 Title: Neuroimaging, dopamine and neurocognition
 Years: 2010-2012

Name: Patrick McCormick
 Program: University of Toronto Postdoctoral Program
 Degree: Postdoctoral Research Fellowship
 Title: The role of the dopamine D₃ receptor in motivation and reward

Years: 2011-2014

Nsme: Hiroyoshi Takeuchi
 Program: Keio University
 School of Medicine
 Department of Neuropsychiatry
 Tokyo, Japan

Degree: Postdoctoral Research Fellowship
 Title: Extended antipsychotic dosing
 Years: 2012-2018

Name: Jimmy Lee
 Program: Woodbridge Hospital, Singapore
 Program: Postdoctoral Research Fellowship
 Title: Clozapine-induced neutropenia
 Years: 2013-2015

Primary Supervisor – PhD

Name: Peter Turrone
 Program: Institute of Medical Science, University of Toronto
 Degree: Ph.D.
 Title: The relationship between D₂ receptor occupancy and involuntary movements using an animal model
 Years: 2001-2003

Name: Araba Chintoh
 Program: Institute of Medical Science (IMS)
 Degree: Ph.D.
 Title: Antipsychotics and Glucose Dysregulation: An Animal Model
 Years: 2005-2008

Name: George Foussias
 Program: Clinician/Scientist Program
 Department of Psychiatry & Institute of Medical Science (IMS)
 University of Toronto

Degree: Ph.D.
 Title: Deficit states in schizophrenia
 Years: 2007-2013

Name: Margaret Hahn
 Program: Institute of Medical Science
 Degree: Ph.D.
 Title: Antipsychotic-induced glucose dysregulation
 Years: 2009-2011

Name: Gagan Fervaha
 Program: Institute of Medical Science, University of Toronto
 Degree: Ph.D.

- Title: Evaluating motivational impairments in schizophrenia
Years: 2011-
- Name: Bashrini Madhu (Co-Supervisor)
Program: School of Medicine, Sri Lanka
Degree: Ph.D.
Title: Outcome of patients with schizophrenia: A prospective follow up study of an incidence and a prevalence cohort
Years: 2012-
- Name: Jennie Pouget
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Investigating the role of immune genes in schizophrenia
Years: 2012-
- Name: Tina Behdinan
Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: Neuroimaging predictors of functional outcome and social cognition in schizophrenia
Years: 2013-
- Name: Eric Plitman
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Assessing glutamatergic dysfunction in the associative striatum of patients with treatment-resistant schizophrenia (TRS)
Years: 2013-
- Name: Mehala Subramaniapillai
Program: Department of Exercise Sciences, University of Toronto
Degree: M.Sc.
Title: Determining the effects of an acute bout of physical activity on executive function among individuals with schizophrenia
Years: 2014-
- Name: Eric Huang
Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: The pharmacogenetics of treatment response in schizophrenia
Years: 2014-
- Name: Ishraq Siddiqui (Co-Supervisor)
Program: Institute of Medical Science (IMS)
Degree: Ph.D.
Title: Behavioural and neurobiological investigation of motivation in schizophrenia: a focus on novelty, engagement, and social

Years: interaction
2015-

Primary Supervisor – MSc

Name: Jean Kwon
Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: Compliance in schizophrenia outpatients taking oral antipsychotics
Years: 1998-1999

Name: Huma Saeedi
Program: Institute of Medical Science
Degree: M.Sc.
Title: Cognitive and behavioral correlates of D₂ transience
Years: 2002-2003

Name: Steve Mann
Program: Institute of Medical Science (IMS)
Degree: M.Sc.
Title: Antipsychotic-induced weight gain: an animal model
Degree: M.Sc.
Years: 2006-2008

Name: Melanie Guenette
Program: Institute of Medical Science
Degree: M.Sc.
Title: Antipsychotic receptor binding and glucose dysregulation
Years: 2010-2012

Name: Laura Schulze
Program: Institute of Medical Science
Degree: M.Sc.
Title: Antipsychotic tolerance: an animal model
Years: 2012-2014

Name: Joshua Lister
Program: Institute of Medical Science
Degree: M.Sc.
Title: Strategies to reduce antipsychotic-related tardive dyskinesia (TD)
Years: 2013-2015

Primary Supervisor - BSc

Name: Ishraq Siddiqui
Program: University of Toronto
Neuroscience Specialist Co-op Program
Degree: B.Sc.
Title: Evaluation of novelty exploration and social interaction in schizophrenia

Years: 2012-2013

Name: Sabrina Phan
Neuroscience Specialist Co-op Program

Program: University of Toronto

Degree: B.Sc.

Title: Trajectories and dimensions of response in treatment-resistant schizophrenia (TRS)

Years: 2013

Primary Supervisor – University of Toronto, Department of Psychiatry Clinician Researcher Program

Name: Dr. George Foussias
Focus: Negative symptoms in schizophrenia
Dates: 2004-2009

Name: Dr. Jessica Thoma
Focus: Social values in first-episode schizophrenia
Dates: 2010-2014

Name: Sr. Suze Berkhout
Focus: Adherence in schizophrenia
Dates: 2012-

Name: Dr. Araba Chintoh
Focus: Antipsychotic-related side effects
Dates: 2013-

Thesis Committees

Name: Cynthia Fu
Program: Institute of Medical Science (IMS)
Title: Noradrenergic dysfunction in the prefrontal cortex in depression: an [¹⁵O] H₂O PET study of the neuromodulatory effects of clonidine
Years: 1998 – 1999

Name: Ivan Kraljevic
Program: Department of Pharmacy, University of Toronto
Degree: M.Sc.
Title: A cost comparison of typical and atypical depot antipsychotics
Years: 2000 – 2002

Name: Joanne Proceviat
Program: Dept. of Pharmaceutical Sciences, CAMH
Degree: Canadian Hospital Pharmacy Residency (BScPhm)
Title: A descriptive analysis of the effectiveness of a pharmacist in the identification of drug related problems in an outpatient mental health clinic

- Years: 2000-2001
- Name: Livia Martucci
Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: Dopamine, GABA, and glutamate system genes in schizophrenia
Years: 2001 – 2002
- Name: April Collins
Program: Ontario Institute of Education (OISE), University of Toronto
Degree: Ph.D.
Title: An educational intervention to enhance awareness of illness and treatment adherence in schizophrenia
Years: 2000 – present
- Name: Dr. David Mamo
Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: Aging and neuroleptic sensitivity: a study of aging effects on relationship between D2 receptor occupancy and catalepsy in rats
Years: 2001-2003
- Name: Monica Hazra
Program: Dept. of Pharmaceutical Sciences, CAMH
Degree: Canadian Hospital Residence Pharmacy (BScPhm)
Title: Introducing a pharmaceutical-care monitoring tool specific for antipsychotic emergent diabetes and hyperlipidemia for inpatients at CAMH
Years: 2001-2002
- Name: Dr. Tony Cohn
Program: Department of Nutritional Sciences, University of Toronto
Degree: M.Sc.
Title: Diabetes susceptibility in drug-free schizophrenia patients and metabolic changes after second generation antipsychotics
Years: 2004-2006
- Name: Edward McAnanama
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Investigating regulation of recall memory in schizophrenia
Years: 2006-present
- Name: Dr. Michele Korostil
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Practice-related learning in schizophrenia: an fMRI investigation
Years: 2007-

Name: Patrick McCormick
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Pre-clinical evaluation of [¹¹C]-(+)-PHNO as an agonist positron emission tomography (PET) radiotracer for imaging of the agonist high-affinity, functional state of the dopamine D₂ receptor
Years: 2007-2010

Name: Carol Lam
Program: Department of Physiology, University of Toronto
Degree: M.Sc.
Title: CNS nutrient sensing, energy and glucose homeostasis
Years: 2007-2009

Name: Rudy Hwang
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Pharmacogenetic analysis of dopamine and glutamate receptor gene polymorphisms and clinical response to clozapine in patients with schizophrenia
Years: 2008-2013

Name: Ava Elahipanah
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Eye-tracking to examine visual span and visual search selectivity in schizophrenia
Years: 2008-2013

Name: Peter Gorczynski
Program: Department of Exercise Sciences, Faculty of Physical Education and Health, University of Toronto
Degree: Ph.D.
Title: Dissecting the 'obesogenic' environment of CAMH service users
Years: 2008-2013

Name: Clair Yang
Program: Department of Physiology, University of Toronto
Title: Hypothalamic AMPK in the control of glucose production
Degree: M.Sc.
Years: 2009-2011

Name: Nabilah Chowdhury
Program: Institute of Medical Science, University of Toronto
Title: Genetics of antipsychotic-induced weight gain
Degree: Ph.D.
Years: 2009-2014

Name: David Greiss
Program: Department of Pharmacology, University of Toronto
Title: Antipsychotics and increased morbidity in schizophrenia
Degree: M.Sc.
Years: 2011-2015

Name: Michele Korostil
Program: Institute of Medical Science, University of Toronto
Title: Network modulation and learning in schizophrenia
Degree: Ph.D.
Years: 2011-

Name: Philip Gerresten
Program: Institute of Medical Science, University of Toronto
Title: fMRI and deficit symptoms in schizophrenia
Degree: Ph.D.
Years: 2011-2015

Name: Tristram Lett
Program: Institute of Medical Science, University of Toronto
Title: Treating working memory deficits in patients with schizophrenia using rTMS and genetic prediction of response
Degree: Ph.D.
Years: 2011-2015

Name: Rachel Rabin
Program: Institute of Medical Science, University of Toronto
Title: Effects of cannabis abstinence on cognitive function in schizophrenia
Degree: Ph.D.
Years: 2012-

Name: Danielle Taylor
Program: Institute of Medical Science, University of Toronto
Title: Antipsychotic response and glutamate system genes
Degree: M.Sc.
Years: 2012

Name: Mark Duncan
Program: Behavioural Medicine, University of Toronto
Title: Affective and physiological responses to exercise in patients with schizophrenia
Degree: M.Sc.
Years: 2012-2014

Name: Hiren Patel
Program: Institute of Medical Science, University of Toronto

Title: Examining cardiorespiratory fitness in diabetic individuals with and without schizophrenia
 Degree: M.Sc.
 Years: 2012-2014

Examination Committees

Name: Dr. Albert Wong
 Program: Institute of Medical Science, University of Toronto
 Degree: Ph.D.
 Title: Identification and analysis of candidate genes for schizophrenia based on the neonatal ventral striatum.
 Year: September, 2001

Name: Dr. Jeff Daskalakis
 Program: Institute of Medical Science, University of Toronto
 Degree: Ph.D.
 Title: Cortical inhibition in schizophrenia
 Year: July, 2002

Name: Luc Boulay
 Program: Department of Psychology, Carleton University
 Degree: Ph.D.
 Title: Contrasting the effects of haloperidol and olanzapine on attention and working memory in schizophrenia: a double-blind flexible dose study
 Year: April, 2003

Name: Dr. Lashmi Voruganti
 Program: Institute of Medical Science, University of Toronto
 Degree: Ph.D.
 Title: Neuroleptic dysphoria
 Year: October, 2003

Name: Alison Yung
 Program: School of Medicine, University of Melbourne
 Degree: Doctor of Medicine
 Title: The prodromal phase of schizophrenia and related psychoses: identification and intervention
 Year: December, 2003

Name: Francoise Ko
 Program: Department of Pharmacology, University of Toronto
 Degree: Ph.D.
 Title: Is dopamine supersensitivity related to elevated D₂ high dopamine receptors and associated genes in animal models of psychosis?
 Year: July, 2006

Name: Ava Elahipanah

Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: Mechanisms of visual search impairment among patients with schizophrenia
Year: January, 2007

Name: Dr. Romina Mizrahi
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Linking phenomenology, anatomy and pharmacology of antipsychotic treatment
Year: May, 2007

Name: Faranak Farazan
Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: Selective deficits in inhibition of gamma oscillations in the dorsolateral prefrontal cortex in schizophrenia
Year: September, 2008

Name: Dr. Valerie Taylor
Program: Department of Psychiatry, McMaster University
Degree: Ph.D.
Title: Metabolic syndrome in mood disorders
Year: December, 2008

Name: Faranak Farazan
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Transcranial magnetic stimulation and electroencephalography on modulation of gamma oscillations in schizophrenia
Year: July, 2010

Name: Mera Barr
Program: Institute of Medical Science, University of Toronto
Degree: Ph.D.
Title: Modulation of gamma oscillatory activity through repetitive transcranial magnetic stimulation in healthy subjects and patients with schizophrenia
Year: October, 2010

Name: Tracy Bhikram
Program: Institute of Medical Science, University of Toronto
Degree: M.Sc.
Title: Neural circuitry in obsessive compulsive disorder: an fMRI study of the effect of IV citalopram
Year: September, 2012

Name: Nina Bahl
 Program: Institute of Medical Science, University of Toronto
 Degree: M.Sc.
 Title: Investigation of neuroplasticity in Parkinson's disease patients with chronic deep-brain stimulation
 Year: December, 2012

Name: Natasha Radhu
 Program: Institute of Medical Science, University of Toronto
 Degree: Ph.D.
 Title: Inhibition of gamma oscillation as a neurophysiological endophenotype in schizophrenia
 Year: April, 2015

Name: Mary LaPierre
 Program: Department of Physiology
 Degree: M.Sc.
 Title: Glucagon action in the dorsal vagal complex and the regulation of glucose homeostasis during high protein-feeding
 Year: May, 2015

H. Elective Supervisor

Name:	Iliya Khramov
Program/Institution:	Undergraduate Program, Summer Award Dept. of Medicine, University of Toronto, Toronto, Ontario
Nature of Elective:	Research
Title:	Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics
Dates:	June – September 2000
Name:	Aristotle Voineskos
Program/Institution	Undergraduate Program, Summer Award Dept. of Medicine, University of Toronto, Toronto, Ontario
Nature of Elective:	Research
Title:	Role of the dopamine D ₃ receptor in tardive dyskinesia
Dates:	June – September, 2002
Name:	George Foussias
Program/Institution:	Undergraduate Program, Dept. of Psychiatry Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia
Nature of Elective:	Clinical
Dates:	Sept. 29 – Oct. 17, 2003
Name:	Ryan VanLieshout
Program/Institution:	Undergraduate Program, Dept. Of Psychiatry Faculty of Medicine, University of Ottawa, Ottawa, Ontario

Nature of Elective:	Clinical
Dates:	Nov. 3 – Nov. 23, 2003
Name:	Ishpuneet Chhabra
Program/Institution:	University of Toronto (Scarborough) Dept. of Psychology - Behavioural Disorders
Nature of Elective:	Co-Op
Dates:	September – December 2009
Name:	Javaid Naima
Program/Institution:	University of Toronto Behavioural Biology & Neurosciences
Nature of Elective:	Animal and Human Drug Trials
Dates:	November 2009-August 2010
Name:	Kathryn McDonald
Program/Institution:	University of Toronto (Scarborough) Dept. of Psychology - Behavioural Disorders
Name of Elective:	Co-Op
Dates:	January – April 2010
Name:	Christopher Tsoutsoulas
Program/Institution:	University of Toronto (Scarborough) Dept. of Psychology - Neurosciences
Name of Elective:	Co-Op
Dates:	May-August 2010
Name:	Larissa Ferguson
Program/Institution:	University of Toronto (Scarborough) Dept. of Psychology - Neurosciences
Name of Elective:	Co-Op
Dates:	September-December 2010
Name:	Cerasela Betlen, MD
Program/Institution:	University of Toronto, Department of Psychiatry
Name of Elective:	Psychopharmacology – MAPS
Dates:	July-December 2011
Name:	Serge LeBlanc, MD
Program/Institution:	University of Toronto, Department of Psychiatry
Name of Elective:	Psychopharmacology – MAPS
Dates:	September 2010-June 2012
Name:	Araba Chintoh
Program/Institution:	University of Newcastle, United Kingdom
Name of Elective:	Undergraduate Selective

Dates:	April-May 2012
Name:	Helen Mik
Program/Institution:	University of Toronto, Department of Psychiatry
Name of Elective:	Psychopharmacology – MAPS
Dates:	September 2012-June 2013
Name:	Jonathan Tay
Program/Institution:	University of Toronto (Scarborough) Dept. of Psychology
Name of Elective:	Co-Op
Dates:	January-August 2013
Name:	Daphne Voineskos
Program/Institution:	University of Toronto, Department of Psychiatry
Name of Elective:	Psychopharmacology – MAPS
Dates:	July-December 2013

Gary Remington
October 29, 2015